



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/62, 9/68, C07K 14/56, 14/78, 14/52, A61K 48/00, 38/17, 38/19		A1	(11) International Publication Number: WO 99/16889
			(43) International Publication Date: 8 April 1999 (08.04.99)
(21) International Application Number: PCT/US98/20464		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 30 September 1998 (30.09.98)			
(30) Priority Data: 60/060,609 1 October 1997 (01.10.97) US			
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): BOLANOWSKI, Mark, A. [US/US]; 5795 Shelton Drive, St. Charles, MO 63304 (US). CAPARON, Maire, H. [IE/US]; 109 Beechwood Court, Chesterfield, MO 63017 (US). CASPERSON, Gerald, F. [US/US]; 314 Claymont Drive, Ballwin, MO 63011 (US). GREGORY, Susan, A. [US/US]; 8136 Cornell Court, University City, MO 63130 (US). KLEIN, Barbara, K. [US/US]; 12917 Topping Estates, St. Louis, MO 63131 (US). McKEARN, John, P. [US/US]; 18612 Babler Meadows Drive, Glencoe, MO 63038 (US).		With international search report.	
(74) Agents: BENNETT, Dennis, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).			


(54) Title: FUSION PROTEINS COMPRISING AN ANGIOSTATIN MOIETY AND THEIR USE IN ANTI-TUMOR TREATMENT

(57) Abstract

The present invention relates to the development of novel multi-functional proteins (MFPs) of the formula: $R_1-L_1-R_2$, $R_2-L_1-R_1$, $R_1-L_1-R_1$, R_1-R_2 , R_2-R_1 , or R_1-R_1 where R_1 is angiostatin, R_2 is selected from endostatin, human type I interferon, thrombospondin, interferon-inducible protein 10, platelet factor 4, and L_1 is a linker capable of linking R_1 to R_2 . The invention is also drawn to nucleic acids that encode MFPs, procedures for manufacturing MFPs, methods of using MFPs, methods of treating angiogenic-mediated disease with MFPs including methods of treating tumors with MFPs, and treating tumors by gene therapy using vectors that encode MFPs.

Selected cloned angiostatin fragments containing kringle domains preceded by an IL-3 signal peptide

Angiostatin fragments



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

FUSION PROTEINS COMPRISING AN ANGIOSTATIN MOIETY AND THEIR USE IN ANTI-TUMOR TREATMENT

Priority

The present application claims priority under Title 35, United States Code, § 119 of United States Provisional application Serial No. 60/060,609 filed October 2, 1997.

Field of the Invention

The present invention relates to the development of novel multi-functional proteins (MFPs) of the formula: $R_1-L_1-R_2$, $R_2-L_1-R_1$, $R_1-L_1-R_1$, R_1-R_2 , R_2-R_1 , or R_1-R_1 , where R_1 is angiostatin, R_2 is selected from endostatin, human type I interferon, thrombospondin, interferon-inducible protein 10, platelet factor 4, and L_1 is a linker capable of linking R_1 to R_2 . The invention is also drawn to nucleic acids that encode MFPs, procedures for manufacturing MFPs, methods of using MFPs, methods of treating angiogenic-mediated disease with MFPs including methods of treating tumors with MFPs, and treating tumors by gene therapy using vectors that encode MFPs.

Background of the Invention

Angiogenesis, the growth of new blood vessels, plays an important role in cancer growth and metastasis. In humans, the extent of vasculature in a tumor has been shown to correlate with the patient prognosis for a variety of cancers (Folkman, J., *Seminars in Medicine of the Beth Israel Hospital, Boston* **333**(26): 1757-1763, 1995; Gasparini, G., *European Journal of Cancer* **32A**(14): 2485-2493, 1996; Pluda, J. M., *Seminars in Oncology* **24**(2): 203-218, 1997). In normal adults, angiogenesis is limited to well controlled situations, such as wound healing and the female reproductive system (Battegay, E.J., *J Mol Med* **73**:333-346, 1995; Dvorak, H.F., *New Engl J Med*, **315**: 1650-1659, 1986)

Animal studies suggest that tumors can exist in a dormant state, in which tumor growth is limited by a balance between high rates of proliferation and high rates of apoptosis (Holmgren, L. et al., *Nat. Med. (N. Y.)* **1**(2): 149-153, 1995; Hanahan, D. et al., *Cell (Cambridge, Mass.)* **86**(3): 353-364, 1996). The switch to an angiogenic phenotype allows tumor cells to escape from dormancy and to grow rapidly, presumably as the result of a decrease in the apoptotic rate of the tumor

cells (Bouck, *Cancer Cells*, **2** (6): 179-185, 1999; Dameron et al., *Cold Spring Harb Symp Quant Biol*, **59**: 483-489, 1994). The control of angiogenesis is thought to be a balance between factors which promote new vessel formation and anti-angiogenic factors which suppress the formation of a neovasculature (Bouck, N. et al., *Advances in Cancer Research* **69**: 135-173, 1996; O'Reilly et al., *Cell (Cambridge, Mass)* **79**(2): 315-328, 1994).

A variety of pro-angiogenic factors have been characterized including basic and acid fibroblast growth factors (bFGF and aFGF) and vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) (Potgens, A. J. G. et al., *Biol. Chem. Hoppe-Seyler* **376**: 57-70, 1995; Ferrara, N., *European Journal of Cancer* **32A**(14): 2413-2442, 1996; Bikfalvi, A. et al., *Endocrine Reviews* **18**: 26-45, 1997). Several endogenous anti-angiogenic factors have also been characterized, including angiostatin (O'Reilly et al., *Cell (Cambridge, Mass)* **79**(2): 315-328, 1994), endostatin (O'Reilly et al., *Cell (Cambridge, Mass)* **88**(2): 277-285, 1997), interferon alpha (Ezekowitz et al., *N. Engl. J. Med.*, May 28, **326**(22): 1456-1463, 1992), thrombospondin (Good et al., *Proc Natl Acad Sci USA* **87**(17): 6624-6628, 1990; Tolsma et al., *J Cell Biol* **122**(2): 497-511, 1993), and platelet factor 4 (PF4) (Maione et al., *Science* **247**(4938): 77-79, 1990).

Angiostatin is a 38 kD protein comprising the first three or four kringle domains of plasminogen and was first described in 1994 (O'Reilly, M. S. et al., *Cell (Cambridge, Mass.)* **79**(2): 315-328, 1994). Mice bearing primary (Lewis lung carcinoma-low metastatic) tumors did not respond to angiogenic stimuli such as bFGF in a corneal micropocket assay and the growth of metastatic tumors in these mice was suppressed until the primary tumor was excised. The factor responsible for the inhibition of angiogenesis and tumor growth was designated mouse angiostatin. Angiostatin was also shown to inhibit the growth of endothelial cells in vitro.

Human angiostatin can be prepared by digestion of plasminogen by porcine elastase (O'Reilly et al., *Cell* **79**(2): 315-328, 1994) or with human metalloelastase (Dong et al., *Cell* **88**, 801-810, 1997). The angiostatin produced via porcine elastase digestion inhibited the growth of metastases and primary tumors in mice. O'Reilly et al. (*Cell* **79**(2): 315-328, 1994) demonstrated that human angiostatin inhibited metastasis of Lewis lung carcinoma in SCID mice. The same group (O'Reilly, M. S. et al., *Nat. Med. (N. Y.)* **2**(6): 689-692, 1996) subsequently showed that human angiostatin inhibited the growth of the human tumors PC3 prostate carcinoma, clone A colon carcinoma, and MDA-MB breast carcinoma in SCID mice. Human

angiostatin also inhibited the growth of the mouse tumors Lewis lung carcinoma, T241 fibrosarcoma and M5076 reticulum cell carcinoma in C57Bl mice. Because these enzymatically-prepared angiostatins are not well characterized biochemically, the precise composition of the molecules is not known.

5 Angiostatins of known composition can be prepared by means of recombinant DNA technology and expression in heterologous cell systems. Recombinant human angiostatin comprising Kringle domains one through four (K1-4) has been produced in the yeast *Pichia pastoris* (Sim et al., *Cancer Res* **57**: 1329-1334, 1997). The recombinant human protein inhibited growth of endothelial
10 cells in vitro and inhibited metastasis of Lewis lung carcinoma in C57Bl mice. Recombinant murine angiostatin (K1-4) has been produced in insect cells (Wu et al., *Biochem Biophys Res Comm* **236**: 651-654, 1997). The recombinant mouse protein inhibited endothelial cell growth in vitro and growth of primary Lewis lung carcinoma *in vivo*. These experiments demonstrated that the first four kringle
15 domains are sufficient for angiostatin activity but did not determine which kringle domains are necessary.

 Cao et al. (*J. Biol. Chem.* **271**: 29461-29467, 1996), produced fragments of human plasminogen by proteolysis and by expression of recombinant proteins in *E. coli*. These authors showed that kringle one and to a lesser extent kringle four of
20 plasminogen were responsible for the inhibition of endothelial cell growth in vitro. Specifically, kringles 1-4 and 1-3 inhibited at similar concentrations, while K1 alone inhibited endothelial cell growth at four-fold higher concentrations. Kringles two and three inhibited to a lesser extent. More recently Cao et al. (*J Biol Chem* **272**: 22924-22928, 1997), showed that recombinant mouse or human kringle five
25 inhibited endothelial cell growth at lower concentrations than angiostatin (K1-4). These experiments demonstrated in vitro angiostatin-like activity but did not address in vivo action against tumors and their metastases.

 World patent applications WO 95/29242 A1, WO 96/41194 A1, and WO 96/35774 A2 describe the expression, purification, and characterization of
30 angiostatin. WO 95/29242 A1 951102 discloses purification of a protein from blood and urine by HPLC that inhibits proliferation of endothelial cells. The protein has a molecular weight between 38 kilodaltons and 45 kilodaltons and an amino acid sequence substantially similar to that of a murine plasminogen fragment beginning at amino acid number 79 of a murine plasminogen molecule. WO
35 96/41194 A1 961219, discloses compounds and methods for the diagnosis and monitoring of angiogenesis-dependent diseases. WO 96/35774 A2 961114 discloses

the structure of protein fragments, generally corresponding to kringle structures occurring within angiostatin. It also discloses aggregate forms of angiostatin, which have endothelial cell inhibiting activity, and provides a means for inhibiting angiogenesis of tumors and for treating angiogenic-mediated diseases.

5 Endostatin, a 20-kDa (184 amino acid) carboxy fragment of collagen XVIII, is an angiogenesis inhibitor produced by a hemangioendothelioma (O'Reilly, M. S. et al., *Cell (Cambridge, Mass.)* **88**(2): 277-285, 1997); and WO 97/15666). Endostatin specifically inhibits endothelial proliferation and inhibits angiogenesis and tumor growth. Primary tumors treated with non-refolded suspensions of *E.*
10 *coli*-derived endostatin regressed to dormant microscopic lesions. Toxicity was not observed and immunohistochemical studies revealed a blockage of angiogenesis accompanied by high proliferation balanced by apoptosis in tumor cells.

 Interferon alpha (IFN alpha) is a family of highly homologous, species-specific proteins that possess complex antiviral, antineoplastic and
15 immunomodulating activities (Extensively reviewed in the monograph "Antineoplastic agents, interferon alfa", American Society of Hospital Pharmacists, Inc., 1996). Interferon alpha also has anti-proliferative, and anti-angiogenic properties, and has specific effects on cellular differentiation (Sreevalsan, in "Biologic Therapy of Cancer", pp. 347-364, (eds. V.T. DeVita Jr., S. Hellman, and
20 S.A. Rosenberg), J.B. Lippincott Co, Philadelphia, PA, 1995).

 Interferon alpha is effective against a variety of cancers including hairy cell leukemia, chronic myelogenous leukemia, malignant melanoma, and Kaposi's sarcoma. The precise mechanism by which IFN alpha exerts its anti-tumor
25 activity is not entirely clear, and may differ based on the tumor type or stage of disease. The anti-proliferative properties of IFN alpha, which may result from the modulation of the expression of oncogenes and/or proto-oncogenes, have been demonstrated on both tumor cell lines and human tumors growing in nude mice (Gutterman, J. U., *Proc. Natl. Acad. Sci., USA* **91**: 1198-1205, 1994).

 Interferon is also considered an anti-angiogenic factor, as demonstrated
30 through the successful treatment of hemangiomas in infants (Ezekowitz et al. *N. Engl. J. Med.*, May 28, **326**(22) 1456-1463, 1992) and the effectiveness of IFN alpha against Kaposi's sarcoma (Krown, *Semin Oncol* **14**(2 Suppl 3): 27-33, 1987). The mechanism underlying these anti-angiogenic effects is not clear, and may be the
35 result of IFN alpha action on the tumor (decreasing the secretion of pro-angiogenic factors) or on the neo-vasculature. IFN receptors have been identified on a variety

of cell types (Navarro et al., *Modern Pathology* **9**(2): 150-156, 1996).

United States Patent 4,530,901, by Weissmann, describes the cloning and expression of IFN-alpha-type molecules in transformed host strains. United States Patent 4,503,035, Pestka, describes an improved processes for purifying 10 species of human leukocyte interferon using preparative high performance liquid chromatography. United States Patent 5,231,176, Goeddel, describes the cloning of a novel distinct family of human leukocyte interferons containing in their mature form greater than 166 and no more than 172 amino acids.

United States Patent 5,541,293, by Stabinsky, describes the synthesis, cloning, and expression of consensus human interferons. These are non-naturally occurring analogues of human (leukocyte) interferon-alpha assembled from synthetic oligonucleotides. The sequence of the consensus interferon was determined by comparing the sequences of 13 members of the IFN-alpha family of interferons and selecting the preferred amino acid at each position. These variants differ from naturally occurring forms in terms of the identity and/or location of one or more amino acids, and one or more biological and pharmacological properties (e.g., antibody reactivity, potency, or duration effect) but retain other such properties.

Thrombospondin-1 (TSP-1) is a trimer containing three copies of a 180 kDa polypeptide. TSP-1 is produced by many cell types including platelets, fibroblasts, and endothelial cells (see Frazier, *Curr Opin Cell Biol* **3**(5): 792-799, 1991) and the cDNA encoding the subunit has been cloned (Hennessy et al., 1989, *J Cell Biol* **108**(2): 729-736; Lawler and Hynes, *J Cell Biol* **103**(5): 1635-1648, 1986). Native TSP-1 has been shown to block endothelial cell migration *in vitro* and neovascularization *in vivo* (Good et al, *Proc Natl Acad Sci USA* **87**(17): 6624-6628, 1990). Expression of TSP-1 in tumor cells also suppresses tumorigenesis and tumor-induced angiogenesis (Sheibani and Frazier, *Proc Natl Acad Sci USA* **92**(15): 6788-6792, 1995; Weinstat-Saslow et al., *Cancer Res* **54**(24): 6504-6511, 1994). The anti-angiogenic activity of TSP-1 has been shown to reside in two distinct domains of this protein (Tolsma et al, *J Cell Biol* **122**(2): 497-511, 1993). One of these domains consists of residues 303 to 309 of native TSP-1 and the other consists of residues 481 to 499 of TSP-1. Another important domain consists of the sequence CSVTCG which appears to mediate the binding of TSP-1 to some tumor cell types (Tuszynski and Nicosia, *Bioessays* **18**(1): 71-76, 1996). These results suggest that CSVTCG, or related sequences, can be used to target other moieties to tumor cells. Taken together, the available data indicate that TSP-1 plays a role in the growth

and vascularization of tumors. Subfragments of TSP-1, then, may be useful as anti-angiogenic components of chimeras and/or in targeting other proteins to specific tumor cells. Subfragments may be generated by standard procedures (such as proteolytic fragmentation, or by DNA amplification, cloning, expression, and purification of specific TSP-1 domains or subdomains) and tested for anti-angiogenic or anti-tumor activities by methods known in the art (Tolsma et al. *J Cell Biol* **122**(2): 497-511, 1993; Tuszynski and Nicosia, *Bioessays* **18**(1): 71-76, 1996).

A variety of *in vivo* experiments demonstrate that chemokines platelet factor 4 (PF-4) and interferon inducible protein 10 (IP-10) retard the growth of tumors. PF-4 blocks the growth of primary tumors in mice (mouse melanoma and human colon cancer) (Sharpe et al., *J. Natl. Cancer Inst.* **82**, 848-853; Maione et al. *Cancer Res.* **51**, 2077-2083, 1991). IP-10 administration blocks non-small cell lung tumorigenesis and Burkitt's lymphoma subcutaneous tumors in mice (Arenberg et al., *J. Exp. Med.* **184**, 981-992, 1996; Sgardari et al. *Proc. Natl. Acad. Sci. USA* **93**, 13791-13796, 1996). PF-4 is currently in clinical trials for Kaposi's sarcoma, glioblastoma, melanoma, renal cell and colon cancer. IP-10 promotes the migration of activated lymphocytes to the site of injection thereby suggesting that IP-10 may have immuno-modulatory properties. The immuno-modulatory property may contribute to the anti-tumor capacity of IP-10.

Anti-angiogenic therapy may offer several advantages over conventional chemotherapy for the treatment of cancer. Anti-angiogenic agents have low toxicity in preclinical trials and development of drug resistance has not been observed (Folkman, J., *Seminars in Medicine of the Beth Israel Hospital, Boston* **333**(26): 1757-1763, 1995). As angiogenesis is a complex process, made up of many steps including invasion, proliferation and migration of endothelial cells, it can be anticipated that combination therapies may be most effective. In fact, combinations of chemotherapy with anti-angiogenic therapy have already shown promising results in pre-clinical models (Teicher, B. A. et al., *Breast Cancer Research and Treatment* **36**: 227-236, 1995; Teicher, B. A. et al., *European Journal of Cancer* **32A**(14): 2461-2466, 1996).

Chimeras of angiostatin with other anti-angiogenic proteins such as endostatin may have improved biological properties by virtue of acting through several mechanisms. The two proteins may have distinct mechanisms, allowing increased efficacy by virtue of blocking the angiogenic process at two separate points. Alternatively, the two proteins may act on the same cell type causing an


increased binding, or other action, by virtue of increased avidity. In this case, each molecule would also have the effect of targeting the other domain to the appropriate site of action. Dimers or higher order multimers of angiostatin, endostatin, or other anti-angiogenic proteins with themselves or other proteins could have increased efficacy and/or potency by virtue of either of these mechanisms.

One class of mechanisms for improved activity of angiostatin chimeras would result from the ability to bind to two distinct receptors on the same cell (e.g., receptor agonists) and thus demonstrate improved activity due to interactions with receptors on a single cell. These chimeras may have improved therapeutic properties through a variety of mechanisms such as: 1). alterations in the overall on- or off-rates or K_d or K_i of the ligand(s) on the target cell, 2). activation or blockade of complementary receptor signaling pathways, and/or 3). more specific targeting of one or both of the components to the cell of interest. Examples of this class are endothelial cell binding dual receptor agonists (or antagonists) such as: A₂B₂-angiostatin, angiostatin-IP-10, and angiostatin-IFN alpha. For example, formation of a chimera between angiostatin and a non-ELR-C-X-C chemokine is expected to generate a receptor agonist which has anti-angiogenic effects on the endothelium. In addition, an IP-10-angiostatin chimera would be expected to contain an immunomodulatory component affecting the recruitment of white blood cells to the tumor. IP-10 would also be expected to have an effect on the primary tumor and on metastasis. Further, the chimeric proteins are expected to possess a unique pharmacokinetic distribution and clearance profile (Dehmer et al. *Circulation*, **91**, 2188-2194, 1995; Tanaka et al. *Nature Medicine*, **3**, 437-442, 1997).

A second class of mechanisms does not depend on receptor binding on the same cell, but where the chimeric protein has improved properties *in vivo* compared to the two components individually. This may be a result of alterations in biodistribution or half-life. Alternatively, the binding of the chimera to one or more of the receptors, pharmacokinetics, or uptake of the chimera is altered in a favorable manner. These proteins are likely to act through complementary mechanisms. Therefore, chimeric proteins containing anti-proliferative and anti-angiogenic activities may provide improved anti-tumor activity by using two distinct mechanisms to decrease tumor growth. The anti-proliferative moiety should act directly on the tumor to decrease its growth while the anti-angiogenic factor should act indirectly by preventing the growth of the neo-vasculature required for rapid tumor growth. One example of this mechanism might include angiostatin/IFN alpha chimeras.

Summary of the Invention

Novel proteins of this invention are represented by the formulas:



wherein R_1 is a modified human angiostatin amino acid sequence,

5 and R_2 is a modified endostatin, human type I interferon, thrombospondin or a fragment thereof, interferon-inducible protein 10, platelet factor 4, and proteins with similar activity,

and wherein L_1 is a linker capable of linking R_1 to R_2 ,

10 and said protein can optionally be immediately preceded by (methionine¹), (alanine¹), (methionine², alanine¹), (serine¹), (methionine², serine¹), (cysteine¹), or (methionine², cysteine¹).

Preferably, R_1 is selected from the from the group consisting of angiostatin K1, angiostatin K5, angiostatin K1-K3, angiostatin K1-K4, or a functional homologue thereof.

15 Preferably R_2 is selected from the from the group consisting of interferon alpha A/D and interferon alpha 2b.

Even more preferably, R_2 is selected from the group consisting of interferon alpha 2a, interferon alpha 2b, interferon alpha hybrid A/D, type I interferon variants, and consensus interferon, or a functional homologue or variant protein thereof.

20

Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the multi-functional proteins, related microbial and eukaryotic expression systems, and processes for making the multi-functional proteins. The invention also relates to pharmaceutical compositions containing the multi-functional proteins, and methods for using the multi-functional proteins.

25

Definitions

The term "multi-functional protein" means a single polypeptide which inherently possesses two distinct activities. In the context of the current invention,

anti-angiogenic and/or anti-tumor activities are contemplated. The polypeptide may be formed by the covalent union of two distinct proteins or portions thereof, or two copies of the same protein, or portions thereof.

5 The term "anti-tumor" means possessing an activity which slows or abolishes the growth of, or which kills, or otherwise harms tumors *in vivo*.

The term "native sequence" refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

10 The terms "mutant amino acid sequence," "mutant protein," "variant protein", "mutein", or "mutant polypeptide" refer to a polypeptide having an amino acid sequence which varies from a native sequence due to amino acid additions, deletions, substitutions, or all three, or is encoded by a nucleotide sequence from an intentionally-made variant derived from a native sequence.

15 The term "angiostatin" means a protein fragment of the heavy chain (SEQ ID NO: 37) of plasminogen having anti-angiogenic activity. The activity of said fragments can be determined by the mouse corneal micropocket assay of angiogenesis or by inhibition of endothelial cell growth *in vitro*.

20 The term "kringle" or "K" means a fragment or substructure of plasminogen or angiostatin bounded by disulfide-linked cysteine residues, and which retain a structure similar to that which it will adopt within the whole of plasminogen. A kringle domain may also include interkringle sequences which serve to connect it with other kringle domains. The terms K1, K2, K3, K4, K5 refer to specific kringle domains, and terms like K1-3 or K2-4, for example, refer to contiguous protein segments from the first kringle through the last kringle in a series, including the interkringle sequences.

25 The term "interferon" includes one of a group of proteins having anti-viral and anti-tumor activities including type I interferon, type I interferon variants, interferon alpha 2a, interferon alpha 2b, interferon alpha hybrid A/D, consensus interferon, functional homologues thereof, and those encoded by a DNA sequences related to those in SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID
30 NO: 31.

The term "thrombospondin" means the proteins identical or essentially identical to thrombospondin and internal fragments of thrombospondin which possess anti-angiogenic activity.

Brief Description of the Figures

Figure 1 shows a schematic of selected cloned angiostatin fragments containing kringle domains preceded by an IL-3 signal peptide

5 The labels K1, K2, K3, K4, and K5, refer to specific kringle domains within human plasminogen or angiostatin. Plasmid pMON24624 contains the sequence of the heavy chain of human plasminogen including the N-terminal peptide (NTP) and the signal peptide (SP). Plasmids pMON24625 (K1-K4), pMON24626 (K1-K3), pMON24627 (K2-K4), pMON24628 (K2-K3), and pMON24650 (K1), each contain various kringle domains, preceded by the IL-3 signal peptide (IL3). These
10 plasmids also contain sequences necessary for expression and secretion of the proteins from mammalian (e.g., BHK) cells.

Figure 2 shows a schematic of selected cloned angiostatin fragments containing kringle domains

15 The plasmid pMON24642 encodes kringles K1-K4 plus additional human plasminogen sequences at its 5' and 3' ends shown in the diagram by solid areas. Plasmids pMON24643 (K1-K4), pMON24644 (K2-K3), pMON24645 (K2-K3), pMON24646 (K1-K3), and pMON24648 (K1) contain specific kringle domains of human plasminogen. These plasmids also contain sequences necessary for the expression of the encoded polypeptides in *E. coli*.

20 **Figure 3 shows a schematic of selected angiostatin/interferon alpha 2b chimeric fusion proteins**

Plasmid pMON20413 encodes the K1 kringle domain fused to interferon alpha through a Glycine-Serine (Gly-Ser) linker peptide. Plasmid pMON20414 is similar to PMON20413, but encodes a chimeric fusion protein containing interferon
25 alpha at its N-terminus fused to the Gly-Ser linker, which is fused to the K1 kringle domain of plasminogen (angiostatin). Plasmid pMON20416 encodes a fusion protein consisting of kringle domains K1-K3 fused to interferon alpha with a Gly-Ser linker.

30 **Figure 4 shows a schematic of selected angiostatin/interferon alpha A/D chimeric fusion proteins**

Plasmid pMON20412 encodes kringles K1-K3 fused to the hybrid A/D interferon with a Gly-Ser linker. Plasmid pMON20420 encodes a fusion protein

containing the hybrid A/D interferon fused to kringles K1-K3 through a Gly-Ser linker. Plasmid pMON20421 encodes kringle K1 fused to the hybrid A/D interferon with a Gly-Ser linker. Plasmid pMON20422 encodes a fusion protein containing the hybrid A/D interferon fused to kringle K1 through a Gly-Ser linker.

5 **Figure 5 shows the proliferation of Daudi cells in the presence of interferon A/D and an interferon A/D K1-3 angiostatin chimeric protein**




Two replicates of assays depicting the proliferation of Daudi cells in the presence of interferon A/D (standard, from Genzyme) and an interferon A/D K1-3 angiostatin chimeric protein are shown. Protein samples were serially diluted,
10 beginning at a concentration of 1 mM.

Detailed Description of the Invention

The present invention encompasses multi-functional proteins (MFPs) which inherently possess two distinct activities. In the context of this invention, anti-angiogenic and/or anti-tumor activities are contemplated. The polypeptide
15 may be formed by the covalent union of two distinct proteins, or portions thereof. Each distinct protein segment which may act through a different and specific cell receptor to initiate complementary biological activities. The MFPs may also be formed from covalently-linked polypeptides derived from the same protein.

Peptide-bonded chimeric fusion proteins

20 Novel compounds of this invention are represented by a formula selected from the group consisting of:



Where R_1 and R_2 are as defined above.

R_1 is preferably a protein or protein fragment with a different but complementary activity than R_2 . Complementary activity is meant to be activity which enhances or changes the response to another cell modulator. The R_1 polypeptide is joined either directly or through a linker segment to the R_2 polypeptide. The term "directly" defines multi-functional proteins in which the polypeptides are joined without a peptide linker. Thus L_1 represents a chemical bond or polypeptide segment to which both R_1 and R_2 are joined in frame. Most commonly L_1 is a linear peptide in which R_1 and R_2 are joined by amide bonds, linking the carboxy terminus of R_1 to the amino terminus of L_1 and carboxy terminus of L_1 to the amino terminus of R_2 . "Joined in frame" means that there is no translation termination or disruption between the reading frames of the DNA encoding R_1 and R_2 .

Additionally, this invention encompasses the use of modified R_1 or R_2 molecules or mutated or modified DNA sequences encoding these R_1 or R_2 molecules. The present invention also includes multi-functional proteins in which R_1 or R_2 is a variant.

The linking group (L_1) is generally a polypeptide of between 1 and 500 amino acids in length. The linkers joining the two molecules are preferably designed to (1) allow the two molecules to fold and act independently of each other, (2) not have a propensity for developing an ordered secondary structure which could interfere with the functional domains of the two proteins, (3) have minimal hydrophobic characteristics which could interact with the functional protein domains and (4) provide steric separation of R_1 and R_2 such that R_1 and R_2 could interact simultaneously with their corresponding receptors on a single cell. Typically surface amino acids in flexible protein regions include Gly, Asn and Ser. Virtually any permutation of amino acid sequences containing Gly, Asn and Ser would be expected to satisfy the above criteria for a linker sequence. Other neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. Additional amino acids may also be included in the linkers due to the addition of unique restriction sites in the linker sequence to facilitate construction of the multi-functional proteins.

Preferred L_1 linkers of the present invention include sequences selected from the group of formulas:

poly(Ser)_n (SEQ ID NO. 44),
poly(Ser)_n (SEQ ID NO. 45)

GlySer¹⁰ (SEQ ID NO. 90)
 GlySer¹⁰ (SEQ ID NO. 91) or
 GAlaGlySer¹⁰ (SEQ ID NO. 92).

One example of a highly-flexible linker is the glycine and serine-rich spacer
 5 region present within the pIII protein of the filamentous bacteriophages, e.g.
 bacteriophages M13 or fd (Schaller et al., *PNAS USA* **72**: 737-741, 1975). This
 region provides a long, flexible spacer region between two domains of the pIII
 surface protein. The spacer region consists of the amino acid sequence:

10 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGluGlyGlyGlySerGlu
 GlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer (SEQ ID NO. 93)

The present invention also includes linkers in which an endopeptidase
 recognition sequence is included. Such a cleavage site may be valuable to separate
 the individual components of the multi-functional protein to determine if they are
 15 properly folded and active *in vitro*. Examples of various endopeptidases include,
 but are not limited to, plasmin, enterokinase, kallikrein, urokinase, tissue
 plasminogen activator, clostripain, chymosin, collagenase, Russell's viper venom
 protease, post-proline cleavage enzyme, V8 protease, Thrombin and factor Xa.

Peptide linker segments from the hinge region of heavy chain
 20 immunoglobulins IgG, IgA, IgM, IgD or IgE provide an angular relationship
 between the attached polypeptides. Especially useful are those hinge regions where
 the cysteines are replaced with serines. Preferred linkers of the present invention
 include sequences derived from murine IgG gamma 2b hinge region in which the
 cysteines have been changed to serines. These linkers may also include an
 25 endopeptidase cleavage site. Examples of such linkers include the following
 sequences:

IleSerGluProSerGlyProIleSerThrIleAsnProSerProProSerLys
 GluSerHisLysSerPro (SEQ ID NO. 94) and
 30 IleGluGlyArgIleSerGluProSerGlyProIleSerThrIleAsnProSer
 ProProSerLysGluSerHisLysSerPro (SEQ ID NO. 95).

The present invention is, however, not limited by the form, size or number
 of linker sequences employed. The only requirement of the linker is that it does
 35 not functionally interfere with the folding and function of the individual molecules
 of the multi-functional protein.

Additional peptide sequences may also be added to facilitate purification or
 identification of multi-functional proteins (e.g., poly-His). A highly antigenic

peptide may also be added that would enable rapid assay and facile purification of the multi-functional protein by a specific monoclonal antibody.

Multi-functional proteins of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to a single factor or by having improved half-life or decreased adverse side effects, or a combination of these properties.

Multi-functional proteins which have little or no activity maybe useful as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful muteins.

Biological activity of the multi-functional proteins of the present invention can be determined by tumor cell proliferation assays, endothelial cell proliferation assays, endothelial cell migration assays, endothelial cell tube formation assays, mouse corneal micro-pocket angiogenesis assays, and tumor growth assays. Syngeneic models of mouse tumor growth, such as the Lewis Lung carcinoma assay (Sugiura and Stock, *Cancer Res.*, **15**: 38-51, 1955; O'Reilly et al., *Cell (Cambridge, Mass)* **79**(2): 315-328, 1994), and xenograft models of human tumors in nude or SCID mice using human breast cancer, prostate carcinoma, or melanoma cell lines are also used (Price, *Breast Cancer Research and Treatment*, **39**: 93-102, 1996; Sasaki et al., *Can. Res.* **55**: 3551-3557, 1995; Pretlow et al., *Can. Res.* **51**: 3814-3817, 1991 and Passaniti et al., *Int. J. Cancer*, **51**: 318-324, 1992; Felding-Habermann et al., *J. Clin. Invest.*, **89**: 2018-2022, 1992).

The biological activity of individual protein subunits can be performed using specific assays. The antiviral activity of interferon, for example, can be carried out by titering the potency of interferon preparations on Madin Darby bovine kidney cells infected with vesicular stomatitis virus (Rubinstein et al., *J. Virol.* **37**(2): 755-758, 1981).

The multi-functional proteins of the present invention may have an improved therapeutic profile as compared to single-acting anti-angiogenic or anti-tumor proteins. For example, some multi-functional proteins of the present invention may have a similar or more potent anti-tumor activity relative to other anti-tumor proteins without having a similar or corresponding increase in side-effects.

Therapeutic targets

5 The multi-functional proteins of the present invention may be useful in the treatment of angiogenic-mediated diseases such as cancer, diabetic retinopathy, and macular degeneration. Among the cancers susceptible to treatment with the polypeptides of the present invention are lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, renal cancer, bladder cancer, melanoma, hepatoma, sarcoma, and lymphoma.

10 The present invention provides an improvement to the existing methods of treating solid tumors, in that it provides methods utilizing multi-functional proteins that have improved biological activities. Therapeutic treatment of tumors with these multi-functional proteins of the present invention may avoid undesirable side effects caused by treatment with presently available drugs. The treatment of solid tumors may include administration of a pharmaceutical composition containing the multi-functional proteins to a patient.

15 Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the multi-functional proteins of the present invention in a mixture with a pharmaceutically acceptable carrier. The compositions can also be admixtures containing adjunctive agents, such as chemotherapeutic or immunotherapeutic agents. This composition can be administered either parenterally, intravenously, or subcutaneously. Other routes of administration are also contemplated, including intranasal and transdermal routes, and by inhalation. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally-acceptable aqueous solution. The preparation of such a parenterally-acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

30 The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering various factors which modify the action of drugs, e.g., the condition, body weight, sex, and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be about 1.0 µg/kg of multi-functional proteins per kilogram of body weight. Dosages would be adjusted relative to the activity of a given multi-functional proteins and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1

35

microgram and as high as 100 milligrams per kilogram of body weight per day.

In addition, there may exist specific circumstances where dosages of multi-functional proteins would be adjusted higher or lower than the range of 0.2 - 100,000 micrograms per kilogram of body weight. These include co-administration with other anti-angiogenic or antitumor proteins or variants; co-administration with adjunctive agents such as chemotherapeutic or immunotherapeutic agents; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated multi-functional proteins; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human anti-tumor proteins.

A non-exclusive list of other appropriate anti-angiogenic or anti-tumor agents or treatments includes chemotherapy, radiation therapy, hormonal therapy, or interleukin-2, or combinations thereof. The dosage recited above would be adjusted to compensate for such additional components in the therapeutic composition.

Delivery of multi-functional proteins to a patient could also be performed through gene therapy. There are a variety of methods, known to those with skill in the art, for introducing genetic material into a host cell. A number of vectors, both viral and non-viral have been developed for transferring therapeutic genes into primary cells. Viral based vectors include: 1) replication deficient recombinant retrovirus (Boris-Lawrie and Temin, *Curr. Opin. Genet. Dev.* **3**:102-109, 1993, Boris-Lawrie and Temin, *Annal. New York Acad. Sci.* **716**:59-71, 1994, Miller, *Current Top. Microbiol. Immunol.* **158**:1-24, 1992) and replication-deficient recombinant adenovirus (Berkner, *BioTechniques* **6**:616-629, 1988, Berkner, *Current Top. Microbiol. Immunol.* **158**:39-66, 1992, Brody and Crystal, *Annal. New York Acad. Sci.* **716**:90-103, 1994). Non-viral based vectors include protein/DNA complexes (Cristiano et al., *PNAS USA* **90**:2122-2126, 1993, Curiel et al., *PNAS USA* **88**:8850-8854, 1991, Curiel, *Annal. New York Acad. Sci.* **716**:36-58, 1994), electroporation and liposome mediated delivery such as cationic liposomes (Farhood et al., *Annal. New York Acad. Sci.* **716**:23-35, 1994).

Cloning and expression of genes encoding multi-functional proteins

The present invention also includes the DNA sequences which code for the multi-functional proteins, DNA sequences which are substantially similar and

perform substantially the same function, and DNA sequences which differ from the DNAs encoding the multi-functional proteins of the invention only due to the degeneracy of the genetic code. Also included in the present invention are the oligonucleotide intermediates used to construct the mutant DNAs and the polypeptides coded for by these oligonucleotides.

Genetic engineering techniques now standard in the art (United States Patent 4,935,233 and Sambrook et al., "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, 1989) may be used in the construction of the DNA sequences of the present invention. One such method is cassette mutagenesis (Wells et al., *Gene* 34:315-323, 1985) in which a portion of the coding sequence in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites.

Pairs of complementary synthetic oligonucleotides encoding the desired gene can be made and annealed to each other. The DNA sequence of the oligonucleotide would encode sequence for amino acids of desired gene with the exception of those substituted and/or deleted from the sequence.

Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent *E. coli* cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with the desired genes.

Cloning of DNA sequences encoding novel multi-functional proteins may be accomplished by the use of intermediate vectors. Alternatively, one gene can be cloned directly into a vector containing the other gene. Linkers and adapters can be used for joining the DNA sequences, as well as replacing lost sequences, where a restriction site was internal to the region of interest. Thus genetic material (DNA) encoding one polypeptide, peptide linker, and the other polypeptide is inserted into a suitable expression vector which is used to transform bacteria, yeast, insect cells or mammalian cells. The transformed organism or cell line is grown and the protein isolated by standard techniques. The resulting product is therefore a new protein which has all or a portion of one protein joined by a linker region to a all or a portion of second protein.

Another aspect of the present invention includes plasmid DNA vectors for use in the expression of these novel multi-functional proteins. These vectors contain the novel DNA sequences described above which code for the novel

polypeptides of the invention. Appropriate vectors which can transform microorganisms or cell lines capable of expressing the multi-functional proteins include expression vectors comprising nucleotide sequences coding for the multi-functional proteins joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the multi-functional proteins. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and which are capable of directing the replication and expression thereof in selected host cells.

Methods for producing the novel multi-functional proteins is another aspect of the present invention. The method of the present invention involves culturing suitable cells or cell lines, which has been transformed with a vector containing a DNA sequence coding for expression of a novel multi-functional protein. Suitable cells or cell lines may be bacterial cells. For example, the various strains of *E. coli* are well-known as host cells in the field of biotechnology. Examples of such strains include *E. coli* strains JM101 (Yanisch-Perron et al. *Gene* **33**: 103-119, 1985) and MON105 (Obukowicz et al., *Applied Environmental Microbiology* **58**: 1511-1523, 1992). Also included in the present invention is the expression of the multi-functional proteins utilizing a chromosomal expression vector for *E. coli* based on the bacteriophage Mu (Weinberg et al., *Gene* **126**: 25-33, 1993). Various strains of *B. subtilis* may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention.

When expressed in the *E. coli* cytoplasm, the gene encoding the multi-functional proteins of the present invention may also be constructed such that at the 5' end of the gene codons are added to encode Met¹-Ala¹, Met²-Ser¹, Met²-Cys¹, or Met¹ at the N-terminus of the protein. The N termini of proteins made in the cytoplasm of *E. coli* are affected by post-translational processing by methionine aminopeptidase (Ben Bassat et al., *J. Bacteriol.* **169**:751-757, 1987) and possibly by other peptidases so that upon expression the methionine is cleaved off the N-terminus. The multi-functional proteins of the present invention may include multi-functional proteins polypeptides having Met¹, Ala¹, Ser¹, Cys¹, Met²-Ala¹, Met²-Ser¹, or Met²-Cys¹ at the N-terminus. These mutant multi-functional proteins may also be expressed in *E. coli* by fusing a secretion signal peptide to the

N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process.

Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary (CHO) cells. General methods for expression of foreign genes in mammalian cells are reviewed in Kaufman, R. J., 1987, "Genetic Engineering, Principles and Methods", Vol. 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional proteins. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, California) can be used. The eukaryotic secretion signal peptide coding region can be from the gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al., *Proc. Natl. Acad. Sci. USA* **84**: 2638-2642, 1987). After construction of the vector containing the gene, the vector DNA is transfected into mammalian cells such as the COS7, HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The polypeptide secreted into the media can be recovered by standard biochemical approaches following transient expression for 24 - 72 hours after transfection of the cells or after establishment of stable cell lines following selection for antibiotic resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, *Nature*, **293**:620-625, 1981, or alternatively, Kaufman et al, *Mol. Cell. Biol.*, **5**(7):1750-1759, 1985) or Howley et al., and U.S. Pat. No. 4,419,446. Other suitable mammalian cell lines are the monkey COS-1 cell line and the CV-1 cell line.

Where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g., Luckow, V.A., *Protein Eng.* J. L. Cleland., Wiley-Liss, New York, NY: 183-218, 1996 and references cited therein. In addition, general methods for expression of foreign genes in insect cells using baculovirus vectors are described in: O'Reilly, D. R., L. K. Miller et al. *Baculovirus Expression Vectors: A Laboratory Manual*. New York, W.H. Freeman and Company, 1992, and King, L. A. and R. D. Possee, *The Baculovirus Expression System: A Laboratory Guide*, London, Chapman & Hall. An expression vector is constructed comprising a baculovirus transfer vector, in which a strong baculovirus promoter (such as the polyhedrin promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-

functional protein. For example, the plasmid pVL1393 (obtained from Invitrogen Corp., San Diego, California) can be used. After construction of the vector carrying the gene encoding the multi-functional protein, two micrograms of this DNA is co-transfected with one microgram of baculovirus DNA into *Spodoptera frugiperda* insect cells, strain Sf9. Alternatively, recombinant baculoviruses can be created using a baculovirus shuttle vector system (Luckow, V.A. et al., *J. Virol.* **67**(8): 4566-4579, 1993, now marketed as the Bac-To-Bac™ Expression System (Life Technologies, Inc. Rockville, MD). Pure recombinant baculovirus carrying the multi-functional protein is used to infect cells cultured, for example, in Excell 401 serum-free medium (JRH Biosciences, Lenexa, Kansas) or Sf900-II (Life Technologies, Inc.). The multi-functional protein secreted into the medium can be recovered by standard biochemical approaches. Supernatants from mammalian or insect cells expressing the multi-functional proteins can be first concentrated using any of a number of commercial concentration units.

The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples. Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

Materials and Methods

General methods

General methods of cloning, expressing, and characterizing proteins are found in T. Maniatis et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1982, and references cited therein, incorporated herein by reference; and in J. Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory, 1989, and references cited therein, incorporated herein by reference.

Unless noted otherwise, all specialty chemicals were obtained from Sigma Co. (St. Louis, MO). Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (Beverly, MA) or Boehringer Mannheim (Indianapolis, IN).

Transformation of E. coli strains

5

E. coli strains (Table 1), such as DH5 α TM (Life Technologies, Gaithersburg, MD) and TG1 (Amersham Corp., Arlington Heights, IL) are used for transformation of ligation reactions and are the hosts used to prepare plasmid DNA for transfecting mammalian cells. *E. coli* strains, such as JM101 (Yanisch-Perron et al., *Gene*, 33: 103-119, 1985) and MON105 (Obukowicz et al., *Appl. and Envir. Micr.*, 58: 1511-1523, 1992) can be used for expressing the multi-functional proteins of the present invention in the cytoplasm or periplasmic space.

TABLE 1 Strains

Designation	Description	Reference/Source
DH5 α TM	F, <i>phi80 dlacZdeltaM15</i> , <i>delta(lacZYA-argF)U169</i> , <i>deoR</i> , <i>recA1</i> , <i>endA1</i> , <i>hsdR17</i> (rk, mk'), <i>phoA</i> , <i>supE44</i> , <i>lambda-</i> , <i>thi-1</i> , <i>gyrA96</i> , <i>relA1</i>	Life Technologies, Rockville, Maryland
JM101 (ATCC#33876)	<i>delta(pro lac)</i> , <i>supE</i> , <i>thi</i> , F'(<i>traD36</i> , <i>proA'B'</i> , <i>lacI'</i> , <i>lacZdeltaM15</i>)	Yanisch-Perron et al., <i>Gene</i> , 33: 103-119, 1985
MON105 (ATCC#55204)	F, <i>lambda-IN</i> (<i>rrnD</i> , <i>rrnE</i>)1, <i>rpoD'</i> , <i>rpoH358</i>	Obukowicz et al., <i>Appl.</i> <i>and Envir. Micr.</i> , 58: 1511- 1523, 1992
MON208	W3110 <i>rpoH358</i> , <i>lacI'</i> , <i>ompT::kan</i>	Alan Easton, Monsanto Company
TG1	<i>delta(lac-pro)</i> , <i>supE</i> , <i>thi-1</i> , <i>hsdD5/F'(traD36, proA'B'</i> , <i>lacI'</i> , <i>lacZdeltaM15</i>)	Amersham Corp., Arlington Heights, Illinois

10

DH5 α TM Subcloning efficiency cells are purchased as competent cells and are ready for transformation using the manufacturer's protocol, while both *E. coli* strains TG1 and MON105 are rendered competent to take up DNA using a CaCl₂ method. Typically, 20 to 50 mL of cells are grown in LB medium (1% Bacto-tryptone, 0.5% Bacto-yeast extract, 150 mM NaCl) to a density of approximately

1.0 optical density unit at 600 nanometers (OD₆₀₀) as measured by a Baush & Lomb Spectronic spectrophotometer (Rochester, NY). The cells are collected by centrifugation and resuspended in one-fifth culture volume of CaCl₂ solution (50 mM CaCl₂, 10 mM Tris-Cl, pH 7.4) and are held at 4°C for 30 minutes. The cells
5 are again collected by centrifugation and resuspended in one-tenth culture volume of CaCl₂ solution. Ligated DNA is added to 0.2 mL of these cells, and the samples are held at 4°C for 30-60 minutes. The samples are shifted to 42°C for two minutes and 1.0 mL of LB is added prior to shaking the samples at 37°C for one hour. Cells from these samples are spread on plates (LB medium plus 1.5% Bacto-agar)
10 containing either ampicillin (100 micrograms/mL, ug/mL) when selecting for ampicillin-resistant transformants, or spectinomycin (75 ug/mL) when selecting for spectinomycin-resistant transformants. The plates are incubated overnight at 37°C.

Colonies are picked and inoculated into LB plus appropriate antibiotic (100
15 ug/mL ampicillin or 75 ug/mL spectinomycin) and are grown at 37°C while shaking.

Cloning and Expression

DNA isolation and characterization

Plasmid DNA can be isolated by a number of different methods and using
20 commercially available kits known to those skilled in the art. Plasmid DNA is isolated using the Promega Wizard™ Miniprep kit (Madison, WI), the Qiagen QIAwell Plasmid isolation kits (Chatsworth, CA) or Qiagen Plasmid Midi or Mini kit. These kits follow the same general procedure for plasmid DNA isolation. Briefly, cells are pelleted by centrifugation (5000 x g), the plasmid DNA released
25 with sequential NaOH/acid treatment, and cellular debris is removed by centrifugation (10000 x g). The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA-binding resin, the column is washed, and plasmid DNA eluted. After screening for the colonies with the plasmid of interest, the *E. coli* cells are inoculated into 50-100 ml of LB plus appropriate antibiotic for
30 overnight growth at 37°C in an air incubator while shaking. The purified plasmid DNA is used for DNA sequencing, further restriction enzyme digestion, additional subcloning of DNA fragments and transfection into *E. coli*, mammalian cells, or other cell types.

Sequence confirmation

Purified plasmid DNA is resuspended in dH₂O and its concentration is determined by measuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic 601 UV spectrometer. DNA samples are sequenced using ABI PRISM™ DyeDeoxy™ terminator sequencing chemistry (Applied Biosystems Division of Perkin Elmer Corporation, Lincoln City, CA) kits (Part Number 401388 or 402078) according to the manufacturer's suggested protocol usually modified by the addition of 5% DMSO to the sequencing mixture. Sequencing reactions are performed in a DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT) following the recommended amplification conditions. Samples are purified to remove excess dye terminators with Centri-Sep™ spin columns (Princeton Separations, Adelphia, NJ) and lyophilized. Fluorescent dye labeled sequencing reactions are resuspended in deionized formamide, and sequenced on denaturing 4.75% polyacrylamide-8M urea gels using ABI Model 373A and Model 377 automated DNA sequencers. Overlapping DNA sequence fragments are analyzed and assembled into master DNA contigs using Sequencher DNA analysis software (Gene Codes Corporation, Ann Arbor, MI).

Mammalian Cell Transfection / Production of Conditioned Media

The BHK-21 cell line can be obtained from the ATCC (Rockville, MD). The cells are cultured in Dulbecco's modified Eagle media (DMEM/high-glucose), supplemented to 2 mM (mM) L-glutamine and 10% fetal bovine serum (FBS). This formulation is designated growth media. Selective media is BHK growth media supplemented with 453 units/mL hygromycin B (CalBiochem, San Diego, CA). The BHK-21 cell line was previously stably transfected with the HSV transactivating protein VP16, which transactivates the IE110 promoter found on the plasmid pMON3359 and pMON3633 and the IE175 promoter found in the plasmid pMON3360B (See Hippenmeyer et al., *Bio/Technology*, pp.1037-1041, 1993). The VP16 protein drives expression of genes inserted behind the IE110 or IE175 promoter. BHK-21 cells expressing the transactivating protein VP16 are designated BHK-VP16. The plasmid pMON1118 (See Highkin et al., *Poultry Sci.*, 70: 970-981, 1991) expresses the hygromycin resistance gene from the SV40 promoter. A similar plasmid, pSV2-hph, is available from ATCC.

BHK-VP16 cells are seeded into a 60 millimeter (mm) tissue culture dish at 3×10^5 cells per dish 24 hours prior to transfection. Cells are transfected for 16 hours in 3 mL of "OPTIMEM"™ (Gibco-BRL, Gaithersburg, MD) containing 10 ug of plasmid DNA containing the gene of interest, 3 ug hygromycin resistance plasmid, pMON1118, and 80 ug of Gibco-BRL "LIPOFECTAMINE"™ per dish.

The media is subsequently aspirated and replaced with 3 mL of growth media. At 48 hours post-transfection, media from each dish is collected and assayed for activity transient conditioned media. The cells are removed from the dish by trypsin-EDTA, diluted 1:10, and transferred to 100 mm tissue culture dishes containing 10 mL of selective media. After approximately 7 days in selective media, resistant cells grow into colonies several millimeters in diameter. The colonies are removed from the dish with filter paper (cut to approximately the same size as the colonies and soaked in trypsin/EDTA) and transferred to individual wells of a 24 well plate containing 1 mL of selective media. After the clones are grown to confluence, the conditioned media is re-assayed, and positive clones are expanded into growth media.

Expression of chimeras in E. coli

E. coli strain MON105 or JM101 harboring the plasmid of interest are grown at 37°C in M9 plus casamino acids medium with shaking in an air incubator Model G25 from New Brunswick Scientific (Edison, NJ). Growth is monitored at OD₆₀₀ until it reaches a value of 1.0 at which time nalidixic acid (10 mg/mL) in 0.1 N NaOH is added to a final concentration of 50 µg/mL. The cultures are then shaken at 37°C for three to four additional hours. A high degree of aeration is maintained throughout culture period in order to achieve maximal production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies (IB). One mL aliquots of the culture are removed for analysis of protein content by boiling the pelleted cells, treating them with reducing buffer and electrophoresis via SDS-PAGE (see Maniatis et al., "Molecular Cloning: A Laboratory Manual", 1982). The culture is centrifuged (5000 x g) to pellet the cells.

Purification

Isolation of Inclusion Bodies

The cell pellet from a 330 mL *E. coli* culture is resuspended in 15 mL of sonication buffer (10 mM 2-amino-2-(hydroxymethyl) 1,3-propanediol hydrochloride (Tris-HCl), pH 8.0 + 1 mM ethylenediaminetetraacetic acid (EDTA). These resuspended cells are sonicated using the microtip probe of a Sonicator Cell Disruptor (Model W-375, Heat Systems Ultrasonics, Inc., Farmingdale, New York). Three rounds of sonication in sonication buffer followed by centrifugation are employed to disrupt the cells and wash the inclusion bodies (IB). The first round of sonication is a 3 minute burst followed by a 1 minute burst, and the final two

rounds of sonication are for 1 minute each.

Extraction and refolding of proteins from inclusion body pellets

5 All steps are at 4°C. Angiostatin K1-4 inclusion bodies were dissolved in 6M urea, 5 mM DTT, 50 mM Bis-Tris Propane, pH 10.8 at 1.2 mg/ml. This solution was stirred for 2 hours and then 6-amino hexanoic acid (stock 1M) was added to achieve a 6 mM concentration, followed by addition of cystine (stock 0.2M, pH 10.5) to 1 mM. This was stirred for 5 minutes and then the K1-4 angiostatin was diluted to 0.2 mg/ml by addition of 75 mM Bis-Tris propane, pH 10.5. It was then stirred for 72 hours to complete the refolding of the protein.

10 *Purification*

Purification of angiostatin K1-4 was achieved using a Sepharose-Lys affinity column followed by Q-Sepharose chromatography. The sample was next dialyzed against 50 mM NaPO₄, pH 8.0 and then filtered through a 1 µm filter to clarify. This sample was loaded onto a Sepharose-Lys column equilibrated in 50 mM NaPO₄, pH 8.0. The load was at approximately 1.5 gm of K1-4 per ml of resin. 15 After loading the column, it was washed with 1 column volume of equilibrating buffer and then K1-4 was eluted using a 10 column volume gradient from 0-8 mM 6-amino hexanoic acid in 50 mM NaPO₄, pH 8.0.

20 Fractions were analyzed by SDS-gel electrophoresis and/or RP-HPLC and pooled. This pool was made 40 mM Tris-Cl, and adjusted to pH 9.0. It was then dialyzed extensively vs. 40 mM Tris-Cl, pH 9.0 and applied to a Q-Sepharose HP column (~5 mgs protein/ml resin) equilibrated in the same buffer. K1-4 was then eluted using a NaCl gradient from 0-0.1M in the equilibrating buffer. Fractions were analyzed by RP-HPLC and/or SDS gel electrophoresis and pooled.

25 In some cases the folded proteins can be affinity-purified using affinity reagents such as monoclonal antibodies or receptor subunits attached to a suitable matrix. Purification can also be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration or hydrophobic chromatography or reversed phase HPLC. These and other protein purification 30 methods are described in detail in Methods in Enzymology, Volume 182 "Guide to Protein Purification" edited by Murray Deutscher. Academic Press, San Diego, California, 1990.

Protein Characterization

The purified protein is analyzed by RP-HPLC, electrospray mass spectrometry, and SDS-PAGE. The protein quantitation is done by amino acid composition, RP-HPLC, and Bradford protein determination. In some cases tryptic peptide mapping is performed in conjunction with electrospray mass spectrometry to confirm the identity of the protein.

Biological Assays

Assay for Human Interferon-Induced Antiviral Activity

Antiviral activity induced by human interferon is measured spectrophotometrically as inhibition of the cytopathic effect that normally results from infection of Madin Darby bovine kidney cells, (ATCC CCL #22), with vesicular stomatitis virus (VSV) (ATCC VR-158) (Rubinstein et al., *J. Virol.* **37**(2): 755-758, 1981). VSV stocks are prepared on mouse L cells (L929) (ATCC CCL# 1). Samples of interferon are serially titrated in a 96-well plate format and incubated with 4×10^4 cells per well, 6 hours prior to addition of virus at a multiplicity of infection of 0.1 plaque forming units per cell. The cells are stained with crystal violet at 20-24 hours postinfection and staining is measured spectrophotometrically at 680 nm. The relative potencies of the samples are compared with Intron A, a recombinant interferon produced by Schering Plough and obtained by prescription.

Inhibitory effect on Proliferation of Daudi Cells

Human Burkitt's lymphoma Daudi cells (ATCC) are seeded at 2×10^4 cells /well into 96-well tissue culture plates and cells are cultured in the presence or absence of serial doses of rhIFN alpha 2b for 3 days. Cultures are pulsed with ^3H -thymidine for the last hour of the culture period, and the ^3H -thymidine uptake, counts per minute (cpm), measured on a Beta-plate reader. All samples are assayed in triplicate.

Endothelial cell proliferation assay

The endothelial cell proliferation assay was performed as described by Cao et al. (*J. Biol. Chem.* **271**: 29461-29467, 1996). Briefly, human dermal microvascular endothelial cells (HdMVEC, Clonetics) or bovine microvascular endothelial cells (BacEnd, Incell) were maintained in MCDB131 containing 5% heat-inactivated fetal bovine serum (FBS, Hyclone), antibiotics, 100 ug/ml heparin (Sigma) and 100 ug/ml endothelial mitogen (Biomedical Technologies). Confluent monolayers at passages 2-5 were dispersed in .05% trypsin and resuspended in

complete medium. Five hundred μ l of complete media containing 1.25×10^4 cells were seeded into wells of a 24-well tissue culture plate coated with 0.1% gelatin (Sigma). The cells were incubated overnight at 37°/5% CO₂ at which time the media was replaced with 250 μ l of media containing 5% FBS and various concentrations of inhibitors. After 30 minutes of incubation, 250 μ l of media containing 1 ng/ml bFGF (R&D Systems) was added and the cells were incubated for an additional 72 hours, at which time they were trypsinized and counted with a Coulter counter.

Endothelial cell in vitro tube formation assay

The tube formation assay is performed as previous described (Gately et al., *Cancer Res.* **56**:4887-4890, 1996). The effect of angiogenesis inhibitors can be tested in an in vitro angiogenesis assay; endothelial cell tube formation on matrix. Matrigel (Becton Dickson) was thawed on ice and diluted 1:1 with MCDB 131 medium supplemented with 2 mM L-glutamine, containing either buffer control or testing compounds. Aliquots of 0.5 ml of 1:1 diluted matrigel were plated into individual wells of 2-chambered Tissue-Tek polystyrene slides (Nunc) and allowed to polymerize at 37°C for at least 30 min. Primary bovine capillary endothelial cells derived from the bovine adrenal cortex (purchased from Incell) were cultured (as described for bovine endothelial cell proliferation). Following trypsinization, the cells were washed three times, then resuspended at 3.5×10^5 cells/ml in MCDB131 medium supplemented with L-glutamine and 1% fetal bovine serum containing either the same buffer control or testing compounds. The endothelial cells (0.5 ml at 3.5×10^5 cells/ml) were plated onto matrigel coated wells containing the same additives. After incubation for 16-24 hours at 37°C in a 5% CO₂ incubator, cultures were evaluated for tube formation (sprouting). Random fields of each experimental condition were photographed using a Nikon N6006 camera under a Nikon Diaphot microscope. The photographs were then quantitated by measuring the total length of the tubes. Tube formation can also be quantitated using image analysis software. Endothelial cell tube networks were fixed in 100% methanol at -20°C for 7-10 min, rinsed 4 times with phosphate buffered saline (PBS) and incubated overnight at 4°C with rabbit polyclonal anti-human Factor VIII-related antigen (von Willibrand factor, vWF) (Dako). The next day, the cells were stained with a secondary antibody, Cy3-conjugated goat anti-rabbit IgG F(ab')₂ specific (Jackson ImmunoResearch Laboratories). Tube formation was visualized using a Nikon microphot-FXA with a fluorescence filter linked to a computer containing image analysis software. Tube formation was measured as follows: Total area encompassed by endothelial cell tubes/Total endothelial cell

surface area

Endothelial cell migration assay

The endothelial cell migration assay is performed essentially as previous described (Gately et al., *Cancer Res.* **56**:4887-4890, 1996). To determine the ability of angiostatin to inhibit the migration of endothelial cells, migration assays were performed in a transwell chamber (Costar) containing 8 mm pore size polycarbonate membranes. The cells utilized in the assay were either human microvascular endothelial cells from Emory or bovine endothelial cells (kindly provided by Gately Northwestern University, Evanston, IL). The cells were starved overnight before use in MCDB131 + 0.1% BSA (human cells) or DMEM+0.1% BSA (bovine cells), harvested, and resuspended in the same media at 10^6 cells/ml. The lower side of the transwells were coated with 0.1% gelatin for 30 minutes at 37°C before addition of 2×10^5 cells to the upper chamber. The transwell was moved to a well containing the chemoattractant (bFGF or VEGF) in the lower chamber. Migration was allowed to occur overnight at 37°C. The membranes were then fixed and stained, and the number of cells that migrated to the lower side of the membrane counted in 3 high powered fields.

Micro-pocket assay to evaluate anti-angiogenic activity

The corneal micropocket assay has been developed to evaluate the anti-angiogenic activity of test compounds in mice. BALBc or C57BL strains of mice are anesthetized with avertin (tribromoethanol, 125 mpk, 0.3-.4 ml/mouse, i.p., 25 ga needle). The eyes are topically anesthetized with 0.5% proparacaine. Only one eye is used. The eye is proptosed with a small forceps and under an operating microscope, a central, intrastromal linear keratotomy is performed with a #15 blade parallel to the insertion of the lateral rectus muscle. A modified cataract knife (1 x 20 mm) is then inserted to dissect a lamellar micropocket to within 1 mm of the temporal limbus. A single Hydron pellet containing either basic fibroblastic growth factor or vascular endothelial growth factor (bFGF or VEGF) is placed on the eye and pushed into the pocket with one arm of the forceps. The flap is self-sealing. Antibiotic ointment (Neobacimyx) is applied once to prevent infection and to decrease irritation of the irregular ocular surface.

Compounds are administered immediately post-operatively. They can be administered either orally, intraperitoneally, subcutaneously or intravenously, depending on bioavailability and potency of the compound. Dosing is from one to three times daily for oral compounds, one or two per day for i.p. or s.q., and once

per day via the tail vein for i.v. delivery. Volumes do not exceed 5 ml/kg orally, 10 ml/kg i.p. or s.q. or 2.5 ml/kg i.v. All injections are done with a 25 guage needle.

5 On post-operative day 5 or 6 the mice are anesthetized with avertin (125 mpk, i.p.), the eyes proptosed, and the degree of neovascularization assessed by determining the maximum vessel length, and the contiguous circumferential zone involved. Using the formula for the area of an ellipse, the neovascular area is measured. The animals receive a thoracotomy while still anesthetized, to assure euthanasia. Some of the eyes are removed for histology. If blood samples are required for compound blood levels, the mice are bled by cardiac puncture immediately following the corneal neovascularization assessment. This is done via a substernal approach with a 1 inch, 23 guage needle, and the animal is subsequently euthanized.

10 Animals are monitored daily following surgery. Topical proparacaine is used as necessary to relieve irritation of the affected eye. The maximum number of bleeds per rat is four, every third day, although typically only two are required, one at day 4 or 6 and one at completion.

Mouse models for anti-tumor activity

20 Several mouse models can be used to evaluate the anti-tumor activity of the chimeric proteins; either direct effects on the growth of the primary tumor or effects on metastasis. These can be divided into two broad classes: syngeneic models of mouse tumor in mice, such as the Lewis Lung Carcinoma (Sugiura and Stock, *Cancer Res.*, 15: 38-51, 1955; O'Reilly et al., *Cell (Cambridge, Mass)* **79**(2): 315-328, 1994) and xenograft models of human tumors in nude or severe combined immunodeficiency (SCID) mice. Examples of the human tumor xenografts include: 25 the breast cancer cell lines, MDA-MB-435 (Price, *Breast Cancer Research and Treatment*, **39**: 93-102, 1996) and MDA-231 (Sasaki et al., *Can. Res.* **55**: 3551-3557, 1995), the human prostate carcinoma cell line, PC-3 (Pretlow et al, *Can. Res.* **51**: 3814-3817, 1991; Passaniti et al., *Int. J. Cancer*, **51**: 318-324, 1992) and the human melanoma line M21 (Felding-Habermann et al., *J. Clin. Invest.*, **89**: 2018-30 2022, 1992).

Examples

Example 1 Construction of plasmids encoding interferon alpha 2b

Construction of pMON30422

An interferon alpha 2b (IFN α -2b) gene was amplified from plasmid DNA from ATCC clone no. 67979 using the primer set, IF start (SEQ ID NO. 1) and IF stop (SEQ ID NO. 2).

5 Oligo IFstart (SEQ ID NO:1)

GATCGACCAT GGTCTTGTGAT CTGCTGCAAA GC 31

10 Oligo IFstop (SEQ ID NO:2)

CGATCGAAGC TTATTATTCT TCACTTCTTA AACTTT 36

The primers were designed to include the appropriate restriction enzyme recognition sites which allow cloning of the gene into expression plasmids. Conditions for polymerase chain reaction (PCR) amplification were 35 cycles 92°C degree, denaturation for one minute, 40°C annealing for one minute and 72°C extension for one minute. A 100 μ l reaction contained 100 pmol of each primer and one μ g of template DNA (isolated by Qiagen Miniprep) and 1x PCR reaction buffer, 200 μ M dNTPs and 0.6 unit Taq DNA polymerase (Boehringer Mannheim). The PCR product was digested with restriction endonucleases *Nco*I and *Hind*III and gel-purified. The vector pMON6875, encoding a *ptac* promoter, G10L ribosome binding site and P22 terminator, was digested with restriction endonucleases *Nco*I and *Hind*III. The digested PCR product and vector fragment were combined and ligated. A portion of the ligation reaction was used to transform *E. coli* strain MON208. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON30422.

Construction of pMON30426

To optimize expression of IFN α -2b in *E. coli*, a new gene with an optimized N-terminus was amplified from plasmid DNA from pMON30422 using the primer set, New IF-A (SEQ ID NO. 3) and IF stop (SEQ ID NO. 2).

30 Oligo IFstop (SEQ ID NO:2)

CGATCGAAGC TTATTATTCT TCACTTCTTA AACTTT 46

35 Oligo NewIF-A (SEQ ID NO:3)

GATCGACCAT GGTCTTGTGAT CTGCTGCAAA TCGATACCAT GGTACCTCTT TCGACCTCTGA 61
TCTGCTCTGGG TTAGATGCGG GGTATCTCTC TTTCTCTCTT CTGAAATGAG AGAGA 116

40 The primers were designed to include the appropriate restriction enzyme

recognition sites which allow cloning of the gene into expression plasmids. Conditions for polymerase chain reaction (PCR) amplification were 35 cycles 92°C denaturation for one minute, 40°C annealing for one minute and 72°C extension for one minute. A 100 ul reaction contained 100 pmol of each primer and one ug of template DNA; and 1x PCR reaction buffer, 200 uM dNTPs and 0.6 unit Taq DNA polymerase (Boehringer Mannheim). The PCR product was digested with restriction endonucleases *NcoI* and *HindIII* and gel-purified. Vector DNA encoding a *ptac* promoter, G10L ribosome binding site and P22 terminator, pMON6875, was digested with restriction endonucleases *NcoI* and *HindIII*. The digested PCR product and vector fragment were combined and ligated. A portion of the ligation reaction was used to transform *E. coli* strain MON208. Transformed bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON30426. Both pMON30422 and pMON30426 encode the same peptide.

15 Example 2. Creation of human interferon alpha A/D chimeras

Construction of pMON20405

Plasmid, pMON30426, DNA was digested with the restriction enzymes *NcoI* and *HindIII* resulting in a 3207 bp vector fragment. Plasmid DNA from pMON30426 was digested with *NcoI* and *BglII* resulting in a 192 bp fragment. The 192 bp fragment along with a 315 bp *BglII/HindIII* fragment that was assembled from synthetic oligonucleotides IFND1 (SEQ ID NO. 11), IFND2 (SEQ ID NO. 12), IFND3X (SEQ ID NO. 13), IFND4X (SEQ ID NO. 14), IFND5 (SEQ ID NO. 15), IFND6 (SEQ ID NO. 16), IFND7 (SEQ ID NO. 17), and IFND8 (SEQ ID NO. 18) was ligated to the vector fragment. A portion of the ligation reaction was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The genetic elements derived from plasmid pMON20405 are the pBR327 origin of replication, the *tac* promoter, the gene 10 leader (g10-L) ribosome binding site joined to human interferon (hIFN) alpha A/D hybrid, the P22 transcriptional terminator, and the streptomycin adenylyltransferase gene.

Construction of pMON20407

Plasmid, pMON31236, DNA was digested with the restriction enzymes *NcoI* and *HindIII* resulting in a 3159 bp vector fragment. Plasmid DNA from pMON20405 was digested with *NcoI* and *HindIII* resulting in a 507 bp fragment

that was ligated to the vector fragment. A portion of the ligation reaction was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and analyzed by restriction analysis. The genetic elements derived from plasmid pMON20407 are the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site joined to human interferon (hIFN) alpha A/D hybrid, the P22 transcriptional terminator, and the streptomycin adenyltransferase gene.

Construction of pMON20408

Plasmid DNA from pMON24646-A7 was mutagenized using the QuikChange Site-Directed Mutagenesis Kit from Stratagene (La Jolla, CA). The *NcoI* site that is present in the K3 domain of human angiostatin was removed by changing base 714 from A to T with synthetic oligonucleotides HPLGN-CD1 (SEQ ID NO. 19) AND HPLGN-CD2 (SEQ ID NO. 20). The genetic elements derived from plasmid pMON20408 are the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site joined to human angiostatin K1-3, the T7 transcriptional terminator and the streptomycin adenyltransferase gene.

Construction of pMON20409

An *NcoI* site was created at the 5' end of the K1-3 angiostatin DNA from plasmid pMON20408 by PCR using Stratagene's *Pfu* DNA polymerase and synthetic oligonucleotides HANGECSK1 (SEQ ID NO. 21) and ANGECSN3 (SEQ ID NO. 22). The PCR reaction was then treated with Taq polymerase (Boehringer Mannheim, Indianapolis, IN), extracted with phenol/chloroform and ligated into the pCR2.1 vector using the TA cloning kit from Invitrogen (San Diego, CA). A portion of the ligation reaction was used to transform competent *E. coli* K-12 strain INVα F'. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert.

Construction of pMON20410

Construction of pMON20410, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding fusion proteins. pMON20410 encodes an IL-3 variant fused 5' to K1-3 angiostatin with the Gly Ser polypeptide linker. The 3551 bp *AflIII*, *HindIII* restriction fragment from pMON31250 was ligated with the 812bp *NcoI*, *HindIII* restriction fragment from

pMON20409. A portion of the ligation reaction was used to transform competent *E. coli* K-12 strain JM101. Transformed bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and was analyzed by restriction analysis and sequenced to confirm the correct insert. The genetic elements derived from the intermediate plasmid pMON20410 are the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, an IL-3 variant joined to human angiostatin K1-3 with the GlySer polypeptide linker, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

10 Construction of pMON20411

The 3552 bp *AflIII*/*HindIII* restriction fragment from pMON31250 was ligated with the 507 bp *NcoI*/*HindIII* bp fragment from pMON20407. A portion of the ligation reaction was used to transform competent *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and was analyzed by restriction analysis. The genetic elements derived from the intermediate plasmid pMON20411 are the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, IL-3 variant joined to human interferon alpha A/D hybrid with the GlySer polypeptide linker, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

20 Construction of pMON20412

Construction of pMON20412, which encodes K1-3 angiostatin fused 5' to the interferon alpha A/D hybrid. Plasmid DNA from pMON20411 was digested with the restriction enzymes *NcoI* and *XmaI* resulting in a 3695 bp vector fragment. Plasmid DNA from pMON20409 was digested with *NcoI* and *MfeI* resulting in a 797 bp fragment that was ligated with an annealed pair of synthetic oligonucleotides K1K3INTU.REQ (SEQ ID NO. 23) and K1K3INTL.REQ (SEQ ID NO. 24) and the vector fragment. A portion of the ligation reaction was used to transform *E. coli* K-12 strain JM101. Transformed bacteria were selected on spectinomycin plates. Plasmid DNA was isolated from a colony grown in LB broth and was analyzed by restriction analysis, and sequenced to confirm the correct insert. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

35 Construction of pMON20420

Construction of pMON20420, which encodes interferon alpha A/D hybrid fused 5' to the K1-3 angiostatin with the Gly Ser polypeptide linker. Plasmid DNA from pMON20410 is digested with the restriction enzymes *Nco*I and *Xma*I resulting in a 4000 bp vector fragment. Plasmid DNA from pMON20407 is digested with *Nco*I and *Acc*I resulting in a 467 bp fragment that is ligated with an annealed pair of synthetic oligonucleotides IFADINTU.REQ (SEQ ID NO. 25) and IFADINTL.REQ (SEQ ID NO. 26) and the vector fragment. A portion of the ligation reaction is used to transform *E. coli* K-12 strain JM101. Transformant bacteria are selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth and was analyzed by restriction analysis, and sequenced to confirm the correct insert. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

Construction of pMON20421

Construction of pMON20421, which encodes K1 angiostatin fused 5' to the interferon alpha A/D hybrid with the Gly Ser polypeptide linker. The 3480 bp *Afl*II/*Hind*III restriction fragment from pMON31251 is ligated with the 507 bp *Nco*I, *Hind*III bp fragment from pMON20407. A portion of the ligation reaction is used to transform competent *E. coli* K-12 strain JM101. Transformant bacteria are selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and analyzed by restriction analysis. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

Construction of pMON20422

Construction of pMON20422, which encodes interferon alpha A/D hybrid fused 5' to the K1 angiostatin with the Gly Ser polypeptide linker. Plasmid DNA from pMON31252 is digested with the restriction enzymes *Nco*I and *Xma*I resulting in a 3391 bp vector fragment. Plasmid DNA from pMON20407 is digested with *Nco*I and *Acc*I resulting in a 467 bp fragment that is ligated with an annealed pair of synthetic oligonucleotides IFADINTU.REQ (SEQ ID NO. 25) and IFADINTL.REQ (SEQ ID NO. 26) and the vector fragment. A portion of the ligation reaction is used to transform competent *E. coli* K-12 strain JM101. Transformed bacteria were selected on spectinomycin plates. Plasmid DNA was

isolated from a colony grown in LB broth and is analyzed by restriction analysis, and sequenced to confirm the correct insert. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

Construction of pMON31250

pMON31250, an intermediate plasmid, was used for the construction of plasmids containing DNA sequences encoding multi-functional proteins. It encodes an IL-3 variant fused 5' to the GlySer polypeptide linker, and contains *Afl*III and *Hind*III cloning sites at the 3' end of the polypeptide linker. The 3159 bp *Nco*I, *Hind*III restriction fragment from pMON31236 was ligated with the 413 bp *Nco*I, *Hind*III fragment from pMON13180. A portion of the ligation reaction was used to transform competent *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and analyzed by restriction analysis. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

Example 3. Creation of angiostatin/interferon alpha 2b chimeras

Construction of pMON20413

Construction of plasmid pMON20413, which encodes K1 angiostatin fused 5' to the interferon alpha 2b sequence. Plasmid pMON31251 was digested with restriction enzymes *Afl*III and *Hind*III, resulting in a 3477 bp *Afl*III/*Hind*III vector fragment. Plasmid pMON30426 which encodes interferon alpha 2b, was digested with *Nco*I and *Hind*III, resulting in release of a 507 bp fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform *E. coli* strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

Construction of pMON20414

Construction of pMON20414, which encodes interferon alpha 2b fused 5' to the K1 angiostatin sequence. Plasmid pMON31252 was digested with the restriction enzymes *Nco*I and *Xma*I, resulting in a 3447 bp *Nco*I/*Xma*I vector

fragment. Plasmid pMON30426, which encodes interferon alpha 2b, was digested with the restriction enzymes *NcoI* and *BspHI*, resulting in a 447 bp *NcoI*/*BspHI* fragment. The 447 bp *NcoI*/*BspHI* fragment from pMON30426 was ligated for 3 h with the following pair of annealed complementary oligonucleotides:

5 Oligo #IFNAintU (SEQ ID NO. 6)

```

CATACATCT TTTTCTTTT TT AAAAAGATT GCAAGAAAT TTAGAAGTA AGGAATACG 61
AAGGGGGGT GGAGGCTCC 62

```

10 Oligo #IFNAintL (SEQ ID NO. 5)

```

GGGGGAGCC TCGAGGGCC TTACGTAAT CATTACTCT TAACTTCT CGAAGCTTC 63
TTAGAAAGA AAAAGATT 64

```

The assembled oligonucleotides create *BspHI* and *XmaI* restriction ends and remove the termination codons from the interferon alpha 2b sequence. This fuses the interferon alpha 2b sequence 5' to the GlySer linker sequence (SEQ ID NO. 79). After 3 h ligation, the mixture was added to the 3447 bp *NcoI*, *XmaI* pMON31252 DNA fragment and the ligation continued for 15 h. This was used to transform *E. coli* strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

Construction of pMON20416

Construction of pMON20416, which encodes K1-K3 angiostatin fused 5' to the interferon alpha 2b sequence. Plasmid pMON31259 was digested with restriction enzymes *AflIII* and *HindIII*, resulting in a 4017 bp *AflIII*, *HindIII* vector fragment. Plasmid pMON30426 which encodes interferon alpha 2b, was digested with *NcoI* and *HindIII*, resulting in a 507 bp *NcoI*, *HindIII* fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform *E. coli* K-12 strain JM101. Transformed bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

Construction of pMON31251

Construction of pMON31251, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding fusion proteins. pMON31251 encodes K1 angiostatin fused 5' to the GlySer linker sequence, and contains *AflIII* and *HindIII* cloning sites at the 3' end of the insert DNA. Plasmid

pMON31250 was digested with restriction enzymes *NcoI* and *XmaI*, resulting in a 3208 bp *NcoI*, *XmaI* vector fragment. Plasmid pMON24649 which encodes the K1 domain of angiotensin was digested with *NcoI* and *EcoRI*, resulting in a 255 bp *NcoI/EcoRI* fragment. The 255 bp *NcoI/EcoRI* fragment from pMON24649 was ligated for 3 h with the following pair of annealed complementary oligonucleotides:

Oligo #K1intU (SEQ ID NO. 8)

GTGTGAACAG GAATACGTAG AGGCGCGCTGG AGGCTCC

37

Oligo #K1intL (SEQ ID NO. 7)

CCGGGGAGCC TCCACCGGCC TCTACGTATT CTTCTTCA

38

The assembled oligonucleotides create *EcoRI* and *XmaI* restriction ends and removes the termination codons from the angiotensin K1 sequence. This fuses the angiotensin K1 sequence to the GlySer linker sequence (SEQ ID NO. 79). After 3 h ligation, the mixture was added to the 3208 bp *NcoI*, *XmaI* pMON31250 DNA fragment and the ligation continued for 15 h. This was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert

20 Construction of pMON31252

Construction of pMON31252, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding fusion proteins. pMON31252 encodes K1 angiotensin fused 3' to the GlySer coding sequence (SEQ ID NO. 79). Plasmid pMON31250 was digested with restriction enzymes *AflIII* and *HindIII*, resulting in a 275 bp *AflIII*, *HindIII* vector fragment. Plasmid pMON24649 was digested with the restriction enzymes *NcoI* and *HindIII*, resulting in a 3552 bp *NcoI/HindIII* fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

30 Construction of pMON31259

Construction of pMON31259, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding fusion proteins. pMON31259 encodes domains K1 through K3 of angiotensin fused 5' to the GlySer

linker sequence (SEQ ID NO. 79) and contains *Afl*III and *Hind*III cloning sites at the 3' end of the insert DNA. Plasmid pMON31250 was digested with restriction enzymes *Nco*I and *Xma*I, resulting in a 3208 bp *Nco*I, *Xma*I vector fragment. Plasmid pMON20409 was digested with *Nco*I and *Mfe*I, resulting in release of a
 5 798 bp *Nco*I/*Mfe*I fragment. The 798 bp *Nco*I/*Mfe*I fragment from pMON20409 was ligated for 3 h with the following pair of annealed complementary oligonucleotides:

Oligo #K1K3intU (SEQ ID NO. 10)

AAATGGCTTA CTTAGAGGCT CATTGAGGCT CC

32

Oligo #K1K3intL (SEQ ID NO. 9)

CTTGGAGGCT TCGACGGGCT TTGAGTAAAG CT

30

The assembled oligonucleotides create *Mfe*I and *Xma*I sites and remove the termination codons from the K1-K3 angiotensin sequence. This fuses the angiotensin K1-K3 sequence to the GlySer linker sequence. After 3 h ligation, the mixture was added to the 3208 bp *Nco*I, *Xma*I pMON31250 DNA fragment and the
 15 ligation continued for 15 h. This was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

Example 4. Construction of plasmids encoding Kringle domains of angiotensin

20 *Construction of pMON24624*

A cDNA encoding the heavy chain of human plasminogen (pMON24624, SEQ ID NO: 37) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers hplgn-s1 (SEQ ID NO: 104) and hplgn-n1 (SEQ ID NO: 105), and using cDNA synthesized from human liver mRNA as a template. This
 25 cDNA encodes the signal peptide, N-terminal peptide and the five Kringle domains of human plasminogen. The resulting DNA was cleaved with the restriction endonuclease *Bam*HI and ligated into the mammalian expression vector pMON3360B, which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B. Plasmid DNA was isolated from
 30 ampicillin-resistant bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24625

A cDNA encoding the first four Kringle domains (K1-4) of human

plasminogen (24625.seq, SEQ ID NO: 38) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angpcr-s1 (SEQ ID NO: 106) and angpcr-n1 (SEQ ID NO: 107). The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the mammalian expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B. Plasmid DNA was isolated from ampicillin-resistant bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA. The resulting protein expressed from pMON24625 includes the human interleukin 3 signal peptide (encoded by vector sequences) fused at the amino terminus of the plasminogen Kringle domains in such a way as to insure secretion of the protein product.

Construction of pMON24626

A cDNA encoding the first three Kringle domains (K1-3) of human plasminogen (24626.seq, SEQ ID NO: 39) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angpcr-s1 (SEQ ID NO: 106) and angpcr-n2 (SEQ ID NO: 108). The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the mammalian expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA. The resulting protein expressed from pMON24626 includes the human interleukin 3 signal peptide (encoded by vector sequences) fused at the amino terminus of the plasminogen Kringle domains in such a way as to insure secretion of the protein product.

Construction of pMON24627

A cDNA encoding Kringle domains two through four (K2-4) of human plasminogen (24627.seq, SEQ ID NO: 40) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angpcr-s2 (SEQ ID NO: 109) and angpcr-n1 (SEQ ID NO: 107). The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the mammalian expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease

cleavage and DNA sequencing to confirm the identity of the cDNA. The resulting protein expressed from pMON24627 includes the human interleukin 3 signal peptide (encoded by vector sequences) fused at the amino terminus of the plasminogen Kringle domains in such a way as to insure secretion of the protein product.

Construction of pMON24628

A cDNA encoding Kringle domains two and three (K2-3) of human plasminogen (24628.seq, SEQ ID NO: 41) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angpcr-s2 (SEQ ID NO: 109) and angpcr-n2 (SEQ ID NO: 108). The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the mammalian expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA. The resulting protein expressed from pMON24628 includes the human interleukin 3 signal peptide (encoded by vector sequences) fused at the amino terminus of the plasminogen Kringle domains in such a way as to insure secretion of the protein product.

Construction of pMON24630

Plasmid pMON24625 was cleaved with restriction endonuclease *BamHI*. The 1161 bp cDNA released by such digestion encodes the first four Kringle (K1-4) domains of human plasminogen fused to the human interleukin 3 signal peptide (24625.seq, SEQ ID NO: 38). The baculovirus expression vector pFastBac1 was cleaved with *BamHI* and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24631

Plasmid pMON24626 was cleaved with restriction endonuclease *BamHI*. The 873 bp cDNA released by such digestion encodes the first three Kringle domains (K1-3) of human plasminogen fused to the human interleukin 3 signal

peptide (24626.seq, SEQ ID NO: 39). The baculovirus expression vector pFastBac1 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24632

Plasmid pMON24625 was cleaved with restriction endonuclease *Bam*HI. The 1161 bp cDNA released by such digestion encodes the first four Kringle (K1-4) domains of human plasminogen fused to the human interleukin 3 signal peptide (24625.seq, SEQ ID NO: 38). The *Pichia pastoris* expression vector pPIC3 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24633

Plasmid pMON24626 was cleaved with restriction endonuclease *Bam*HI. The 873 bp cDNA released by such digestion encodes the first three Kringle domains (K1-3) of human plasminogen fused to the human interleukin 3 signal peptide (24626.seq, SEQ ID NO: 41). The *Pichia pastoris* expression vector pPIC3 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24636

Plasmid pMON24627 was cleaved with restriction endonuclease *Bam*HI. The 909 bp cDNA released by such digestion encodes Kringle domains two through four (K2-4) of human plasminogen fused to the human interleukin 3 signal peptide (24627.seq, SEQ ID NO: 40). The baculovirus expression vector pFastBac1 was

cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and
5 analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity.

Construction of pMON24637

Plasmid pMON24628 was cleaved with restriction endonuclease *Bam*HI. The 621 bp cDNA released by such digestion encodes Kringle domains two and
10 three (K2-3) of human plasminogen fused to the human interleukin 3 signal peptide (24628.seq, SEQ ID NO: 41). The baculovirus expression vector pFastBac1 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to
15 ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity.

Construction of pMON24638

Plasmid pMON24627 was cleaved with restriction endonuclease *Bam*HI. The 909 bp cDNA released by such digestion encodes Kringle domains two through
20 four (K2-4) of human plasminogen fused to the human interleukin 3 signal peptide (24627.seq, SEQ ID NO: 40). The *Pichia pastoris* expression vector pPIC3 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to
25 ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24639

Plasmid pMON24628 was cleaved with restriction endonuclease *Bam*HI. The 621 bp cDNA released by such digestion encodes Kringle domains two and
30 three (K2-3) of human plasminogen fused to the human interleukin 3 signal peptide (24628.seq, SEQ ID NO: 41). The *Pichia pastoris* expression vector pPIC3 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to

prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24642

A cDNA encoding the first four Kringle domains (K1-4*) of human plasminogen (24642.seq, SEQ ID NO: 42) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angeg-s1 (SEQ ID NO: 103) and angeg-n1 (SEQ ID NO: 100). The resulting DNA was cleaved with the restriction endonucleases *Afl*III and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had been cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. In order to optimize expression in *E. coli*, the 5' PCR primer (angee-s1) contained degeneracies at the third positions of the first few codons. This resulted in a population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA. The protein encoded by pMON24642 is a somewhat longer version of the K1-4 encoded by the cDNA in pMON24643.

Construction of pMON24643

A cDNA encoding the first four Kringle domains (K1-4) of human plasminogen (24643 seq, SEQ ID NO: 43) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angeg-s2 (SEQ ID NO: 102) and angeg-n2 (SEQ ID NO: 99). The resulting DNA was cleaved with the restriction endonucleases *Afl*III and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had been cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. In order to optimize expression in *E. coli*, the 5' PCR primer (angee-s2) contained degeneracies at the third positions of the first few codons. This resulted in a population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B

host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

5 *Construction of pMON24644*

A cDNA encoding domains two and three (K2-3) of human plasminogen (24644.seq, SEQ ID NO: 44) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers anged-s3 (SEQ ID NO: 101) and anged-n3 (SEQ ID NO: 98). The resulting DNA was cleaved with the restriction endonucleases
10 *AflIII* and *HindIII* and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *NcoI* and *HindIII*. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. In order to optimize expression in *E. coli*, the 5' PCR primer (anged-s3 SEQ ID NO: 101) contained degeneracies at the third positions of the first few codons. This resulted in a
15 population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease
20 cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24645

A cDNA encoding Kringle domains two through four (K2-4) of human plasminogen (24645.seq, SEQ ID NO: 45) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers anged-s3 (SEQ ID NO: 101) and
25 anged-n2 (SEQ ID NO: 99). The resulting DNA was cleaved with the restriction endonucleases *AflIII* and *HindIII* and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *NcoI* and *HindIII*. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. In order to optimize expression in *E. coli*, the 5' PCR primer (anged-s3) contained
30 degeneracies at the third positions of the first few codons. This resulted in a population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA
35 was isolated from bacterial colonies and analyzed by restriction endonuclease

cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24646

5 A cDNA encoding the first three Kringle domains (K1-3) of human plasminogen (24646.seq, SEQ ID NO: 46) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers anged-s2 (SEQ ID NO: 102) and anged-n3 (SEQ ID NO: 98). The resulting DNA was cleaved with the restriction endonucleases *Afl*III and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. 10 In order to optimize expression in *E. coli*, the 5' PCR primer (anged-s2) contained degeneracies at the third positions of the first few codons. This resulted in a population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA 15 was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24648

20 A cDNA encoding the first Kringle domain (K1) of human plasminogen (24648.seq, SEQ ID NO: 47) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers hanged-sk1 (SEQ ID NO: 110) and anged-n3 (SEQ ID NO: 98). The resulting DNA was cleaved with the restriction endonucleases *Nco*I and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. 25 In order to optimize expression in *E. coli*, the 5' PCR primer (hanged-sk1) contained the same nucleotide sequence found in the K1-3 cDNA in pMON24646. Plasmid DNA was isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened 30 for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24649

A cDNA encoding the first kringle domain of human angiostatin was

synthesized by polymerase chain reaction using the primers Hang-ec-sk1.seq and ang-ec-n4.seq using pMON24646-A7 as template. The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *NcoI* and *HindIII*. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24650

pMON24649 was cleaved with *NcoI* and *HindIII* releasing the cDNA encoding the first Kringle (K1) of human plasminogen (24649.seq, SEQ ID NO: 112). The K1 cDNA was ligated into the mammalian cell expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24652

pMON20412 was cleaved with *NcoI* and *HindIII* releasing the cDNA encoding the first three Kringles of human plasminogen fused to the IFN alpha A/D cDNA. The cDNA was ligated into the mammalian cell expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Example 5. Purification of angiostatin/interferon alpha 2b chimeras

Plasmid pMON24652, encoding an angiostatin K1-3/interferon A/D chimeric protein, was transfected into BHK/VP16 cells and stable cell lines selected as described above in the materials and methods (Hippenmeyer, P. and Highkin, M. Bio/Technology 11: 1037-1041, 1993). Thirty-six clones were isolated and six clones selected for testing in roller bottles. The concentration of the chimeras were determined by ELISA using a commercially-available human IFN-alpha ELISA kit (Biosource #KHC4012). Clone 15 produced the most chimera, 14.4 ug/ml, while the

other five clones produced much less (clones 8, 14, 29, 32, and 36 each produced 1.17, 2.22, 0.04, 0.20, and 1.12 ug/ml, respectively).

A 50 ml lysine sepharose column was pre-equilibrated at 4°C with 50 mM sodium phosphate, pH 7.4. About 500 ml of a 12X concentrate of conditioned serum-free media (SF-BHK) was loaded onto the column at 4°C with a flow rate of about 2.5 ml/min. The column was washed with 50 mM sodium phosphate, pH 7.4, followed by a wash containing 500 mM NaCl in 50 mM sodium phosphate, pH 7.4, to remove non-specific binding proteins. The column was then equilibrated back to a low salt environment with two column volumes of 50 mM sodium phosphate, pH 7.4. The desired chimera was eluted by washing the column with 200 mM epsilon-amino caproic acid in 50 mM sodium phosphate, pH 7.4. Approximately 10.5 ml fractions were collected and the elution monitored by UV absorption. Fractions 4-6 absorbed significant UV and were combined. These fractions were dialyzed three times at 4°C against 4 liters of 50 mM sodium phosphate, pH 7.4, and sterile filtered. Analytical lysine sepharose chromatography yielded a final concentration of about 0.6 mg/ml.

SDS-PAGE analysis of the purified sample on reducing and non-reducing gels indicated that the chimera migrated at a position close to its expected size. Electron spray mass spectrometry indicated a molecular weight of about 51,556 daltons, indicating that the material isolated from BHK cells is partially glycosylated.

The purified chimera was assayed for endothelial cell migration, in triplicate, as described in the materials and methods. The results are shown in the table below:

25 HMEC migration

Sample	Cells/HPF
Media	14.33 ± 3.84
VEGF	190.00 ± 16.46
VEGF + Intron A (500 U/ul)	111.11 ± 25.47
VEGF + IFN A/D (500 U/ul)	131.73 ± 19.90
VEGF + IFN A/D (5000 U/ul)	44.89 ± 18.48
VEGF + Angiostatin K1-K3/IFN A/D (0.3 ug/ul)	73.22 ± 8.80
VEGF + Angiostatin K1-K3/IFN A/D (30 ug/ul)	35.11 ± 18.51
VEGF + Angiostatin K1-K3 prepared from <i>E. coli</i> (30 ug/ul)	130.56 ± 7.04

Interferon alpha A/D from a commercial source (Genzyme) and the angiostatin/IFN A/D chimera were also tested twice in a Daudi cell proliferation assay using a series of 3-fold dilutions, each beginning at a concentration of 1 nM. The interferon A/D and the angiostatin/interferon A/D chimera had similar inhibition profiles (Figure 5).

All references, patents, or applications cited herein are incorporated by reference in their entirety.

Tables

Plasmids

Plasmid	SEQ ID NO.	Marker	Description	Source
pFastBac1		Amp, Gent	Baculovirus donor plasmid containing multiple cloning site downstream of an AcNPV polyhedrin promoter within a mini-Tn7 transposable element.	Life Technologies, Inc.
pPIC3		Amp, HIS3	<i>Pichia pastoris</i> expression vector	Invitrogen Company
pMON3360 B			Mammalian expression vector for use in BHK/VP16 cells	Hippenmeyer, P. and Highkin, M. Bio/Technology 11: 1037-1041, 1993
pMON3633			Mammalian expression vector for use in BHK/VP16 cells	This reference
pMON5723		Spec	Generic Spec-resistant <i>E. coli</i> expression vector containing the <i>E. coli recA1</i> promoter and G10L ribosome binding site	
pMON6875		Spec	Generic Spec-resistant <i>E. coli</i> expression vector containing the <i>E. coli recA1</i> promoter and G10L ribosome binding site	

pMON13180	Amp	Intermediate plasmid containing an IL-3 variant fused to a Gly-Ser polypeptide linker (SEQ ID NO: 79). Contains an <i>NcoI</i> site at the 5' end of the IL-3 variant coding sequences and <i>AflIII</i> and <i>HindIII</i> cloning sites at the 3' end of the linker region.	WO 97/12955
pMON20405	Spec	3207 bp <i>NcoI/HindIII</i> frag from pMON30426 + 192 bp frag from pMON30426 (A portion of IFN alpha) + 315 bp frag from 8 synthetic oligos with <i>BglII/HindIII</i> ends (D portion of IFN alpha). Creates IFN alpha A/D hybrid.	This reference
pMON20407	Spec	3159 bp <i>NcoI/HindIII</i> frag from pMON31236 + 507 bp frag from pMON20405 (IFN alpha A/D hybrid)	This reference
pMON20408	Spec	Removed <i>NcoI</i> site in K3 region of angiostatin K1-K3 in pMON24646-A7	This reference
pMON20409	Spec	Created <i>NcoI</i> site at the 5' end of K1-K3 angiostatin	This reference
pMON20410	Spec	3551 bp <i>AflIII, HindIII</i> fragment from pMON31250 + 812 bp frag from pMON20409 (creates chimera IL-3 variant K1-K3 angiostatin)	This reference

pMON20411		Spec	3551 bp <i>Afl</i> III/ <i>Hind</i> III frag from pMON31250 + 507 bp frag from pMON20407 (creates chimera IL-3 variant/IFN A/D hybrid)	This reference
pMON20412		Spec	3695 bp <i>Nco</i> I/ <i>Xma</i> I frag from pMON20411 + 797 bp <i>Nco</i> I/ <i>Mfe</i> I frag from pMON20409 + 1 pair of synthetic oligonucleotides with <i>Mfe</i> I/ <i>Xma</i> I ends (creates K1- K3/IFN A/D hybrid chimera)	This reference
pMON20413	#35	Spec	3447 bp <i>Afl</i> III/ <i>Hind</i> III fragment from pMON31251 + 507 bp <i>Nco</i> I/ <i>Hind</i> III fragment of pMON30426 (creates K1- GlySer-IFN a2b hybrid)	This reference
pMON20414	#31	Spec	3447 <i>Nco</i> I/ <i>Xma</i> I from pMON312b2 + 447 bp <i>Nco</i> I/ <i>Bsp</i> HI frag from pMON30426 + synthetic oligos with <i>Bsp</i> HI/ <i>Xma</i> I ends (creates IFN a2b-GlySer-K1 hybrid)	This reference
pMON20416	#33	Spec	4017 bp <i>Afl</i> III/ <i>Hind</i> III vector from pMON31259 + 507 bp <i>Nco</i> I/ <i>Hind</i> III fragment from pMON30426 (creates K1-K3- IFN a2b hybrid)	This reference

pMON20420	#30	Spec	4000 bp <i>NcoI/XmaI</i> frag from pMON20410 + 467 bp <i>NcoI</i> . <i>AccI</i> frag from pMON20407 + 1 pair of synthetic oligonucleotides with <i>AccI/XmaI</i> ends (creates IFN A/D hybrid/K1-K3 angiostatin chimera	This reference
pMON20421	#34	Spec	3480 bp <i>AflIII/HindIII</i> frag from pMON31251 + 507 bp <i>NcoI/HindIII</i> frag from pMON20407 creates a chimera of K1/IFN A/D hybrid	This reference
pMON20422	#29	Spec	3491 bp <i>NcoI/XmaI</i> frag from pMON31252 + 467 <i>NcoI/AccI</i> bp frag from pMON20407 + 1 pair of synthetic oligonucleotides with <i>AccI/XmaI</i> ends (creates IFN A/D hybrid/K1 angiostatin chimera)	This reference
pMON24624	#37	Amp	Human plasminogen heavy chain including the native plasminogen signal sequence, N-terminal peptide and kringles 1-5. <i>BamHI</i> fragment in pMON3360B. (Amino acids - 19-537 of plasminogen. nucleotides 55-1752)	This reference

pMON24625	#38	Amp	Human angiostatin(S) including kringles 1-4 of hPlgn. <i>AflIII/HindIII</i> fragment in pMON3633. Seq file includes hIL3 signal sequence contributed by the vector. (Amino acids 79-440 of plasminogen, nucleotides 346- 1431)	This reference
pMON24626	#39	Amp	K1-3 fragment of human angiostatin(S) including kringles 1-3 of hPlgn. <i>AflIII/HindIII</i> fragment in pMON 3633. Seq file includes hIL3 signal sequence contributed by the vector. (Amino acids 79-344 of plasminogen, nucleotides 346- 1143)	This reference
pMON24627	#40	Amp	K2-4 fragment of human angiostatin (S) including kringles 2-4 of hPlgn. <i>AflIII/HindIII</i> fragment in pMON3633. Seq file includes hIL3 signal sequence contributed by the vector. (Amino acids 163-440 of plasminogen, nucleotides 598- 1431)	This reference

pMON24628	#41	Amp	K2-3 fragment of human angiostatin S ₁ including kringle 2-3 of hPlgn. A7III/HindIII fragment in pMON3633. Seq file includes hIL3 signal sequence contributed by the vector. (Amino acids 163-344 of plasminogen, nucleotides 598-1143)	This reference
pMON24630		Amp	K1-4 cDNA (BamHI fragment) from pMON24625 cloned into baculovirus transfer vector pFastBac1.	This reference
pMON24631		Amp	K1-3 cDNA (BamHI fragment) from pMON24626 cloned into baculovirus transfer vector pFastBac1.	This reference
pMON24632		Amp, HIS3	K1-4 cDNA (BamHI fragment) from pMON24625 cloned into <i>Pichia pastoris</i> expression vector pPIC3.	This reference
pMON24633		Amp, HIS3	K1-3 cDNA (BamHI fragment) from pMON24626 cloned into <i>Pichia pastoris</i> expression vector pPIC3.	This reference
pMON24634		Kan, Gent	K1-4 cDNA (BamHI fragment) from pMON24625 transposed into the bacmid bMON14272.	This reference
pMON24635		Kan, Gent	K1-3 cDNA (BamHI fragment) from pMON24626 transposed into the bacmid bMON14272.	This reference

pMON24636	Amp	K2-4 cDNA (<i>Bam</i> HI fragment)	This reference from pMON24627 cloned into baculovirus transfer vector pFastBac1.
pMON24637	Amp	K2-3 cDNA (<i>Bam</i> HI fragment)	This reference from pMON24628 cloned into baculovirus transfer vector pFastBac1.
pMON24638	Amp. HIS3	K2-4 cDNA (<i>Bam</i> HI fragment)	This reference from pMON24627 cloned into <i>Pichia pastoris</i> expression vector pPIC3.
pMON24639	Amp. HIS3	K2-3 cDNA (<i>Bam</i> HI fragment)	This reference from pMON24628 cloned into <i>Pichia pastoris</i> expression vector pPIC3.
pMON24640	Kan. Gent	K2-4 cDNA (<i>Bam</i> HI fragment)	This reference from pMON24627 transposed into the bacmid bMON14272.
pMON24641	Kan. Gent	K2-3 cDNA (<i>Bam</i> HI fragment)	This reference from pMON24628 transposed into the bacmid bMON14272.
pMON24642	#42 spec	Human angiostatin(E). <i>Afl</i> III/ <i>Hind</i> III fragment in pMON5723. The 5' end has been mutagenized for increased expression. (Amino acids 74-470 of plasminogen, nucleotides 331-1464)	This reference

pMON24643	#43	spec	Human angiotatin S. K1-4 <i>A7III/HindIII</i> fragment in pMON5723. Amino acids 79- 440 of plasminogen, nucleotides 346-1431)	This reference
pMON24644	#44	spec	K2-3 fragment of human angiotatin(S). <i>A7III/HindIII</i> fragment in pMON5723. (Amino acids 163-344 of plasminogen, nucleotides 598- 1143)	This reference
pMON24645	#45	spec	K2-4 fragment of human angiotatin(S). <i>A7III/HindIII</i> fragment in pMON5723. (Amino acids 163-440 of plasminogen, nucleotides 598- 1431)	This reference
pMON24646	#46	spec	K1-3 fragment of human angiotatin(S). <i>A7III/HindIII</i> fragment in pMON5723. (Amino acids 79-344 of plasminogen, nucleotides 346- 1143)	This reference
pMON24648	#47	spec	K1 fragment of human angiotatin(S). <i>NcoI/HindIII</i> fragment in pMON5723. (Amino acids 79-184 of plasminogen, nucleotides 7 (24644A7.seq) -607)	This reference

pMON24649	#112	spec	K1 fragment of human angiostatin(S). <i>NcoI/HindIII</i> fragment in pMON5723. (Amino acids 79-184 of plasminogen, nucleotides 1-269 of pMON24646-A7.seq)	This reference
pMON24650	#48	Amp	K1 fragment of human angiostatin(S). <i>NcoI/HindIII</i> fragment in pMON3633. (Amino acids 79-184 of plasminogen)	This reference
pMON24652	#49	Amp	K1-3 fragment of human angiostatin/IFN A/D (<i>NcoI/HindIII</i> fragment from pMON20412) in pMON3633.	This reference
pMON30422	#27	spec	Interferon alpha 2b	This reference
pMON30426	#28	spec	Interferon alpha 2b with optimized N-terminal codons	This reference
pMON31236		Spec	Similar to pMON5723 with the exception of the <i>NcoI/HindIII</i> insert	This reference
pMON31250		Spec	3159 bp <i>NcoI/HindIII</i> frag from pMON31236 + 413 bp <i>NcoI/HindIII</i> fragment from pMON13180 (creates an intermediate for making fusion proteins in the new spec vector)	This reference

pMON31251	Spec	3208 bp <i>NcoI</i> / <i>XmaI</i> fragment of pMON31250 + 255 <i>NcoI</i> / <i>EatI</i> fragment of pMON24649 + synthetic oligos with <i>EatI</i> / <i>XmaI</i> ends (creates K1-Gly-Ser hybrid intermediate plasmid)	This reference
pMON31252	Spec	3552 <i>AflIII</i> / <i>HindIII</i> fragment from pMON31250 + 275 bp <i>NcoI</i> / <i>HindIII</i> fragment from pMON24649 (creates Gly-Ser-angiostatin K1 hybrid)	This reference
pMON31259	Spec	3208 bp <i>NcoI</i> / <i>XmaI</i> fragment of pMON31250 + 798 bp <i>NcoI</i> / <i>MfeI</i> fragment of pMON20409 + synthetic oligos with <i>MfeI</i> / <i>XmaI</i> ends (creates K1-K3-Gly-Ser hybrid intermediate plasmid)	This reference

SEQ ID Correlation table

SEQ ID NO.	SEQ ID Name
1	Oligo Ifstart
2	Oligo Ifstop
3	Oligo NewIF-A
4	Oligo IFADINTL
5	Oligo IFNAINTL
6	Oligo IFNAINTU
7	Oligo K1NTL
8	Oligo K1NTU
9	Oligo K1K3INTL
10	Oligo K1K3INTU
11	Oligo IFND1
12	Oligo IFND2
13	Oligo IFND3X
14	Oligo IFND4X
15	Oligo IFND5
16	Oligo IFND6
17	Oligo IFND7
18	Oligo IFND8
19	Oligo HPLGN-CD1
20	Oligo HPLGN-CD2
21	Oligo HANGECSK1
22	Oligo AN3ECN3
23	Oligo K1K3INTU
24	Oligo K1K3INTL
25	Oligo IFADINTU
26	Oligo IFADINTL
27	30422.seq
28	30426.seq
29	IFN adk1.seq (20422)
30	IFN adk1_3.seq (20420)
31	IFN argk1.seq (20414)
32	IFN argk1_3.seq ()
33	K1_3IFN arg.seq (20416)
34	K1IFN ad.seq (20421)
35	K1IFN arg.seq (20413)
36	K1-K3IFN ad.seq (20412)
37	pMON24624.seq
38	pMON24625_bam.seq
39	pMON24626_bam.seq
40	pMON24627.seq
41	pMON24628.seq
42	pMON24642_B5.seq
43	pMON24643-C10.seq
44	pMON24644-E7.seq
45	pMON24645-33.seq

46 pMON24640.seq
47 pMON24641.seq
48 pMON24650.seq
49 pMON24651.seq
50 huendostatin.seq
51 human_plgn.seq
52 huvasculostatin.seq
53 30433.pep
54 30436.pep
55 IFNadk1.pep
56 IFNadk1_3.pep
57 IFNargk1.pep
58 IFNargk1_3.pep
59 K1-K3IFNarg.pep
60 K1IFNad.pep
61 K1IFNarg.pep
62 K1-K3IFNad.pep
63 pMON24634.pep
64 pMON24635.pep
65 pMON24636.pep
66 pMON24637.pep
67 pMON24638.pep
68 pMON24640.pep
69 pMON24643.pep
70 pMON24644.pep
71 pMON24645.pep
72 pMON24646.pep
73 pMON24648.pep
74 pMON24650.pep
75 pMON24652.pep
76 huendostatin.pep
77 hplaminogen.pep
78 Huvasculostatin.pep
79 Peptide linker, Tyr Val Glu Gly Gly Gly Ser Pro Gly Gly
Gly Ser Gly Gly Gly Ser Asn
80 Peptide linker, Gly Gly Gly Ser
81 Peptide linker, Gly Gly Gly Ser Gly Gly Gly Ser
82 Peptide linker, Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
Ser
83 Peptide linker, Ser Gly Gly Ser Gly Gly Ser
84 Peptide linker, Glu Phe Gly Asn Met Ala
85 Peptide linker, Glu Phe Gly Gly Asn Met Ala
86 Peptide linker, Glu Phe Gly Gly Asn Gly Gly Asn Met Ala
87 Peptide linker, Gly Gly Ser Asp Met Ala Gly
88 Peptide linker 34s
89 Peptide linker 34s
90 Peptide linker 65s
91 Peptide linker AGS

92	Peptide linker G68
93	Peptide linker M13
94	Peptide linker Hinge1
95	Peptide linker Hinge2
96	Oligo hang sk1
97	Oligo hanged_ec_sk1
98	Oligo anged n3
99	Oligo anged n2
100	Oligo anged n1
101	Oligo anged s3
102	Oligo anged s2
103	Oligo anged s1
104	Oligo Hplgn_S1
105	Oligo Hplgn_N1
106	Oligo angpcr_s1
107	Oligo angpcr_n1
108	Oligo angpcr_n2
109	Oligo angpcr_s2
110	Oligo Hang_Ec_Sk1
111	Oligo anged_N4
112	24649.seq
113	24649.pep

Claims

WHAT IS CLAIMED IS:

1. A multi-functional protein, comprising an amino acid sequence of the formula:

$$R_1-L_1-R_2;$$

$$R_2-L_2-R_1;$$

$$R_1-L_3-R_2;$$

$$R_1-R_2;$$

$$R_2-R_1;$$
 and

$$R_1-R_2;$$

wherein R_1 is angiostatin;

and R_2 is selected from endostatin, human type I interferon, thrombospondin, interferon-inducible protein 10 (IP-10), and platelet factor 4;

and wherein L_1 is a linker capable of linking R_1 to R_2 ;

and said protein can optionally be immediately preceded by (methionine¹), (alanine¹), (methionine²), (alanine¹), (serine¹), (methionine²), (serine¹), (cysteine¹), or (methionine², cysteine¹).

2. The multi-functional protein as recited in claim 1, wherein R_1 is selected from the group consisting of angiostatin K1, angiostatin K1-K3, angiostatin K1-K4, angiostatin K1-K5, angiostatin K5, and a functional homologue thereof.

3. The multi-functional protein as recited in claim 1, wherein said type I interferon is selected from the group consisting of type I interferon variants, interferon alpha 2a, interferon alpha 2b, interferon alpha hybrid A/D, consensus interferon, and a functional homologue thereof.

4. The multi-functional protein as recited in claim 1, 2, or 3 wherein said linker (L_1) is one or more peptide sequences selected from the group consisting of;

SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, and a functional homologue thereof.

5. The multi-functional protein of claim 1, wherein the amino acid sequence is selected from the group consisting of
SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID
NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61,
SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID
NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70,
SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID
NO:75,
or a functional homologue thereof.
6. Use of a multi-functional protein fragment of claim 1 for the manufacture of a medicament for therapeutic application to inhibit tumor growth.
7. Use of a multi-functional protein fragment of claim 2 for the manufacture of a medicament for therapeutic application to inhibit tumor growth.
8. Use of a multi-functional protein fragment of claim 3 for the manufacture of a medicament for therapeutic application to inhibit tumor growth.
9. A nucleic acid molecule encoding said multi-functional protein of claim 1.
10. A nucleic acid molecule encoding said multi-functional protein of claim 2.
11. A nucleic acid molecule encoding said multi-functional protein of claim 3.
12. A nucleic acid molecule encoding said multi-functional protein of claim 1, wherein said nucleic acid sequence is selected from the group consisting of
SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID
NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35,
SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID
NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44,
SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID
NO:49,
or a combination or a functional homologue thereof.
13. A method of producing a multi-functional protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 9, 10.

11. or 12 in a manner allowing expression of said multi-functional protein and recovering said multi-functional protein.

5 14. A pharmaceutical composition comprising a therapeutically effective amount of the multi-functional protein according to claim 1, 2, or 3 and a pharmaceutically acceptable carrier.

10 15. The pharmaceutical composition of claim 14 further comprising an adjunctive agent, wherein said adjunctive agent is selected from the group consisting of chemotherapeutic and immunotherapeutic agents.

15 16. A method of treating a human patient with an angiogenic-mediated disease, comprising administering to the patient with an angiogenic-mediated disease an effective amount of multi-functional protein of claim 1.

17. The method of claim 16, wherein the angiogenic-mediated disease is selected from the group consisting of cancer, diabetic retinopathy, macular degeneration, and arthritis.

20 18. A method of modulating tumors in a patient comprising the step of: administering an effective amount of the multi-functional protein as recited in claim 1, 2, or 3 to said patient.

25 19. A method of inhibiting the production of tumor cells in a patient comprising the step of administering an effective amount of the multi-functional protein as recited in claim 1, 2, or 3 to said patient.

30 20. The method of claim 19, wherein the tumor cell is characteristic of one selected from the group consisting of lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, renal cancer, bladder cancer, melanoma, hepatoma, sarcoma, and lymphoma.

35 21. A method for treatment of a patient having a solid tumor, comprising the steps of;

(a) measuring tumor size;

(b) administering an effective dose of multi-functional protein in a vehicle; and


(c) periodically monitoring reduction in tumor size.

22. A method of human gene therapy, comprising delivery of a gene delivery
vehicle to cells in or adjacent to a tumor, said vehicle encoding a multi-
functional protein.
23. A method of claim 22, wherein said vehicle is a vector comprising a nucleic
acid encoding a polypeptide capable of inhibiting tumor growth.
24. A method of claim 22, wherein said multi-functional protein is selected
from the group of proteins as recited in claim 1, 2, 3, 4, or 5.
25. A gene therapy vector comprising a nucleic acid encoding a polypeptide
capable of inhibiting tumor growth.
26. A composition consisting of a therapeutically effective dose of a nucleic acid
encoding a polypeptide capable of inhibiting tumor growth in a
physiologically tolerable diluent.
27. A gene therapy vehicle of claim 26 that is lyophilized.
28. A gene therapy vehicle of claim 26 that is dehydrated.

1 / 4

FIG. 1

Selected cloned angiostatin fragments containing kringle domains preceded by an
IL-3 signal peptide


Angiostatin fragments

2 / 4

FIG. 2


Selected cloned angiotensin fragments containing kringle domains

Angiotensin fragments



3 / 4

FIG. 3

Selected angiotensin/interferon alpha chimeric fusion proteins

4 / 4

FIG. 4


Selected angiostatin/interferon .alpha. A/D chimeric fusion proteins

Figure 5

*Proliferation of Daudi cells in the presence of interferon A/D
and an interferon A/D K1-3 angiostatin chimeric protein*

ANY REFERENCE TO FIGURE 5 SHALL BE CONSIDERED NON-EXISTENT

SEQLIST.TXT

SEQUENCE LISTING

5 <110> Bolanowski, Mark A.
Ceparon, Mairé H.
Caspersen, Gerald F.
Gregory, Susan A.
Klein, Barbara K.
McKearn, John P.

10 <120> Multi-functional Proteins

15 <130> Q-3036

<150> 60-060,609
<151> 1997-10-02

20 <160> 113

<170> FastSEQ for Windows Version 3.0

25 <210> 1
<211> 32
<212> DNA
<213> human

30 <400> 1 32
gatcgacat ggcttgat ctgctcaaa cc

<210> 2
<211> 36
<212> DNA
<213> human

35 <400> 2 36
cgatogaagc ttattatcc ttacttcta aacttt

40 <210> 3
<211> 115
<212> DNA
<213> human

45 <400> 3 60
gatcgacat ggcttgat ctgctcaaa ctatagcc ggtagccgt cgaacccga
tgcctcggc ccagatggc cgtatctctc ttctctcgt ctggaaggac agaca 115

50 <210> 4
<211> 61
<212> DNA
<213> human


```

5      <210> 11
      <211> 71
      <212> DNA
      <213> human

      <400> 11
      gatcttcaac ctgtttacac tcaaaagatc ttctggctgt tgggatgagg aactgtctga
      caattctggt aacgaactgt
      60
      80

10     <210> 12
      <211> 84
      <212> DNA
      <213> human

      <400> 12
      ctgtctgggac agcttgggtgc acaatttggt cagcaggttc tcatcccaag cagccagaaga
      atcttttggtg gtaaacagggt tgaa
      60
      84

20     <210> 13
      <211> 80
      <212> DNA
      <213> human

      <400> 13
      accagcagct gaacgacctc gaagcctgtg tgaagcaggc ggagcgtgtg ggtgaaactc
      cgtctgatga cgtggacttc
      60
      80

30     <210> 14
      <211> 80
      <212> DNA
      <213> human

      <400> 14
      gccagatagg agtccacgtt catcagcggc gtttcaccca cagcctcttc ctgcattaca
      cagccttcca ggtcgttcag
      60
      80

40     <210> 15
      <211> 80
      <212> DNA
      <213> human

      <400> 15
      atcttgcttc tgaagaaata ctcttggtgt atactctgt atctgactga gaagaaatac
      agtcgtcttc ctctggaggt
      60
      80

45     <210> 16
      <211> 80
      <212> DNA
      <213> human

      <400> 16
      ccttaacacg ctctccacga cactgggtgt atctctcttc agtcagatac agagtgtatc
      cctggaatga ctctctcaga
      60
      80

```

<110> 17
 <111> 17
 <112> DNA
 <113> human
 5
 <110> 17
 tttttgtttt gaaatcttggg gtttttttga ttttttttgg aattttttgg aattttttgg 61
 ttttttttga tttttt 75
 10
 <110> 18
 <111> 18
 <112> DNA
 <113> human
 15
 <110> 18
 agtttttttt tttttttttt gttttttttt tttttttttt tttttttttt tttttttttt 61
 tttttttttt g 75
 20
 <110> 19
 <111> 19
 <112> DNA
 <113> human
 25
 <110> 19
 ggaaaaagggg cttttttttt gttttttttt 29
 30
 <110> 20
 <111> 20
 <112> DNA
 <113> human
 35
 <110> 21
 <111> 21
 <112> DNA
 <113> human
 40
 <110> 21
 tttttttttt gttttttttt tttttttttt 35
 45
 <110> 22
 <111> 22
 <112> DNA
 <113> human
 50
 <110> 23
 <111> 23
 <112> DNA
 <113> human

<410> 23
 aattggcctta ctatagaacgyc ggaggagcct cc 32

5 <210> 24
 <211> 32
 <212> DNA
 <213> human

10 <400> 24 32
 ccgggggagcc tccacggccc tctacgtaag cc

15 <210> 25
 <211> 59
 <212> DNA
 <213> human

20 <400> 25 59
 ctaccaactt gcaagaacgt ctccgtccta aggaanacgt agagggcggt ggaggctcc

25 <210> 26
 <211> 61
 <212> DNA
 <213> human

<400> 26 60
 ccgggggagcc tccacggccc tctacgtatt ccttacgacg cagaagttct tgcaggctgg 61

30 <210> 27
 <211> 507
 <212> DNA
 <213> human

35 <400> 27 60
 atgggttttg atctgcctca aacccacagc ctgggttagc ggaggacatt gatgtctctg 120
 gcacagatga ggagaattctc tttttctccc tgcctgaagg acagacatga ctttggattt 130
 ccccaggagg agttttggcaa ccagttccaa aaggctgaaa ccattccctgt cctccatgag 140
 atgattcagc agattctcaa tctcttcagc acaaaggact catctgcctg ttgggacgag 150
 accctcctag acaaattcta cactgaactc taccagcagc tgaatgacct ggaagcctgt 160
 gtgatacagg gggtgggggt gacagagact cccctgatga aggaggaactc cactctgggt 170
 gtgaggaat acttccaaag aatcactctc tatctgaaag acaagaaata cagcccttgt 180
 acctggcagp ttgtcagagc agaaatcag agatctctt ctctgtcaac aaacttgcaa 190
 gaaagtctta gactaagga ataataa

45 <210> 28
 <211> 507
 <212> DNA
 <213> human

50 <400> 28 60
 atgggttttg atctgcctca aacccacagc ctgggttagc ggaggacatt gatgtctctg 120
 gcacagatga ggagaattctc tttttctccc tgcctgaagg acagacatga ctttggattt 130
 ccccaggagg agttttggcaa ccagttccaa aaggctgaaa ccattccctgt cctccatgag 140

[illegible]

16

<010>	20
<011>	621
<012>	DNA
<013>	human

		44512 29						
15		atgggtatgttg	atcttcaggga	aacttctatgg	gtggatagggc	gtggatagggc	gataataggtg	67
		gctttagatcc	gaggtatctc	ctctctctctc	tctttagaagg	atagagcaatga	ctttaggattt	11
		tccttaggact	agctttaggaa	ccagtctctca	tcctctctctca	ccatctctctt	ctcttagctag	160
		atgattcagcc	atattctctca	ccctctctctc	accaaagatc	ctctctctctg	tgggcatgag	240
20		gaactgctgg	acaaattctg	ccctgaactg	ctcttaggagc	tgaagcctct	ggagctctctt	300
		tgcatacag	atgagcgtct	ggttgaaatt	atgtctatga	atgttgagtc	catctcctgct	360
		gttaaggaatt	acttcctctc	ctctctctctg	ctctctctctg	atacaaaata	cagctcctctt	420
		gattggcagg	ctcttcctga	tcctctctctg	ctctctctctt	ctctctctctc	caactctctca	480
25		caactctctc	gagctctctga	ctctctctctg	gtctctctctg	gtctctctctg	tggctctctt	540
		ggggggcgt	cccaactctc	acttctctct	tcctctctctg	agactctctga	tcctctctctt	600
		tcctgagcga	cgatgtctca	acataaaaaa	gtctctctctt	ctctctctctg	gagctctctt	660
		ctctctctca	gactctgatt	ctctctctct	atctctctctt	cagaggggact	ggaggggaaa	720
25		tcctgagcga	atctctctca	cgatctctctg	gtctctctctt	ctctctctctc	ccatctctctg	780
		atagagatctg	actactctga	ctctctctctg	tcctctctctg	aa		820

```

30      <010> 30
      <011> 1059
      <012> DNA
      <013> human

```

	4104-10						
35	aaagttcttgta	aaatgagagta	aactaataga	ctgggttagoo	gttgcacacct	gattgctgta	10
	ttctagagagc	ggcgtatctc	tcctttcttc	tgatttgagg	acagacatga	ctttgggattt	100
	ccctagtagg	agtttggaa	tcagtctcaa	aaggttcgaa	ccatccctgt	ctctccatgag	180
	atgataagc	agatctctca	ctgttcttc	acaaagatc	cttcctgtgc	tggggtgag	240
	gaactgtctg	acaaatcttc	caatgaactc	taccagagc	tgaacagact	agaagctgtc	300
40	gtgatgtagg	aggagagctt	gggtcaaat	ccgtgagta	acgtggaatc	ctctctggct	360
	ctgaacaaat	atttcctgt	tatcaactct	tatttgactg	agaagaaata	cagccctgtt	420
	gcttgggagg	ttcttctgt	tcaaatcttg	gttccctgt	ctctgtctac	caacccgcaa	480
	caatctcttc	ggcgttagga	ctagttagg	ggcgggtgag	ctcccccggg	tgggtcttat	540
	ggcggggctt	caaacatggc	attttatctt	ccaaagctta	agactgggaa	tgaaaagaa	600
45	tacagagctc	cgatgtctca	acaaaaaaat	ggatctccat	gtcaaaaaat	gagtttcaat	660
	ttttcccaaa	gaatttgaat	cttccctctt	acaaagctat	ctaggggact	ggaggtggaac	720
	tactgcagga	atctagagaa	tgatctgttg	tgctctctgt	ctatactac	tcattccaaa	780
	aaagatatct	aactatggga	ctttctcttg	cttcaagagg	aatgtatgct	tggagctggc	840
	caaaaaaatg	aaggcaaaat	ttccaaagac	atgtccgaa	tggaaatcca	ggtctgggaa	900
50	ttctagagct	gaagagcttc	gttatagatt	ctttccaaat	tcaaaaatct	caacctgaa	960
	aaatctctct	gtctgaacct	cttataggag	ttggggctct	ggtctctctc	ctctgagctc	1020
	caaaagctct	gggaaccttg	ctaatatctc	gggtgcaaaa	caatcttacc	attctctggt	1080
	ctctccctac	attgtctcgaa	cccaaacggt	caaaatctac	gggttaatat	ggtctctaac	1140
	gtgtccctggg	caacgtctga	ctcttggaat	gcttggatct	ctcaatctac	tacagagctc	1200

	<p> <210> 31 <211> 932 <212> DNA <213> human </p>	<p> 1000 1100 1200 </p>
5	<p> <400> 31 atgggttggg atctgcccga aactcatagc ctgggttagc gtgcacccc gatgctctg gctcagatgc gccgtatctc tctttctccc tgcctgaagg acagacatga ctttggattc ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccctccctgt cctccatgag atgattccac agatcttcaa tctcttcagg acaaaggact catctgctgc ttgggatgag accctcttag acaaatctca cactgaactc taccagcagc tgaatgacct ggaagcctgt gtgatacagg ggttgggggt gacagagact cccctcatga aggaaggact cattctggct gtgaggaaat acttccaaag aatcactctc tatctgaaag agaagaaata cagcctctgt gcttgggagg ttctcagagg aaaaatcctg agatcttttt ctttgcacac aaacttgcac gaaagtctaa gaagtaagga atactgtagg ggcgggtgag gctcccccgg tgggtgttct ggggggggct ccaacatggc agtttatctt tccagagtga agactgggaa tggaaagaaat taccagaggga cgtgttccaa aacaaaaaat ggcctcactt atcaaaaaat gacttccact cctccccaca gacttagatt cccctctgtt acacacccct cagagggact ggaggagaa tacttcaggga atccagacaa cgtatccgag gggcccttgt gctatactac tcatccagaa aagagatatg actactggga cattctttag tgttaaggag aa </p>	<p> 60 120 180 240 300 360 420 480 540 600 660 720 780 822 </p>
10	<p> <210> 32 <211> 1359 <212> DNA <213> human </p>	
15	<p> <400> 32 atgggttggg atctgcccga aactcatagc ctgggttagc gtgcacccc gatgctctg gctcagatgc gccgtatctc tctttctccc tgcctgaagg acagacatga ctttggattc ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccctccctgt cctccatgag atgattccac agatcttcaa tctcttcagg acaaaggact catctgctgc ttgggatgag accctcttag acaaatctca cactgaactc taccagcagc tgaatgacct ggaagcctgt gtgatacagg ggttgggggt gacagagact cccctcatga aggaaggact cattctggct gtgaggaaat acttccaaag aatcactctc tatctgaaag agaagaaata cagcctctgt gcttgggagg ttctcagagg aaaaatcctg agatcttttt ctttgcacac aaacttgcac gaaagtctaa gaagtaagga atactgtagg ggcgggtgag gctcccccgg tgggtgttct ggggggggct ccaacatggc agtttatctt tccagagtga agactgggaa tggaaagaaat taccagaggga cgtgttccaa aacaaaaaat ggcctcactt atcaaaaaat gacttccact cctccccaca gacttagatt cccctctgtt acacacccct cagagggact ggaggagaa tacttcaggga atccagacaa cgtatccgag gggcccttgt gctatactac tcatccagaa aagagatatg actactggga cattctttag tgttaaggag aa </p>	<p> 60 120 180 240 300 360 420 480 540 600 660 720 780 822 </p>
20	<p> <210> 32 <211> 1359 <212> DNA <213> human </p>	
25	<p> <400> 32 atgggttggg atctgcccga aactcatagc ctgggttagc gtgcacccc gatgctctg gctcagatgc gccgtatctc tctttctccc tgcctgaagg acagacatga ctttggattc ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccctccctgt cctccatgag atgattccac agatcttcaa tctcttcagg acaaaggact catctgctgc ttgggatgag accctcttag acaaatctca cactgaactc taccagcagc tgaatgacct ggaagcctgt gtgatacagg ggttgggggt gacagagact cccctcatga aggaaggact cattctggct gtgaggaaat acttccaaag aatcactctc tatctgaaag agaagaaata cagcctctgt gcttgggagg ttctcagagg aaaaatcctg agatcttttt ctttgcacac aaacttgcac gaaagtctaa gaagtaagga atactgtagg ggcgggtgag gctcccccgg tgggtgttct ggggggggct ccaacatggc agtttatctt tccagagtga agactgggaa tggaaagaaat taccagaggga cgtgttccaa aacaaaaaat ggcctcactt atcaaaaaat gacttccact cctccccaca gacttagatt cccctctgtt acacacccct cagagggact ggaggagaa tacttcaggga atccagacaa cgtatccgag gggcccttgt gctatactac tcatccagaa aagagatatg actactggga cattctttag tgttaaggag aa </p>	<p> 60 120 180 240 300 360 420 480 540 600 660 720 780 822 </p>
30	<p> <210> 32 <211> 1359 <212> DNA <213> human </p>	
35	<p> <400> 32 atgggttggg atctgcccga aactcatagc ctgggttagc gtgcacccc gatgctctg gctcagatgc gccgtatctc tctttctccc tgcctgaagg acagacatga ctttggattc ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccctccctgt cctccatgag atgattccac agatcttcaa tctcttcagg acaaaggact catctgctgc ttgggatgag accctcttag acaaatctca cactgaactc taccagcagc tgaatgacct ggaagcctgt gtgatacagg ggttgggggt gacagagact cccctcatga aggaaggact cattctggct gtgaggaaat acttccaaag aatcactctc tatctgaaag agaagaaata cagcctctgt gcttgggagg ttctcagagg aaaaatcctg agatcttttt ctttgcacac aaacttgcac gaaagtctaa gaagtaagga atactgtagg ggcgggtgag gctcccccgg tgggtgttct ggggggggct ccaacatggc agtttatctt tccagagtga agactgggaa tggaaagaaat taccagaggga cgtgttccaa aacaaaaaat ggcctcactt atcaaaaaat gacttccact cctccccaca gacttagatt cccctctgtt acacacccct cagagggact ggaggagaa tacttcaggga atccagacaa cgtatccgag gggcccttgt gctatactac tcatccagaa aagagatatg actactggga cattctttag tgttaaggag aa </p>	<p> 60 120 180 240 300 360 420 480 540 600 660 720 780 822 </p>
40	<p> <210> 32 <211> 1359 <212> DNA <213> human </p>	
45	<p> <400> 32 atgggttggg atctgcccga aactcatagc ctgggttagc gtgcacccc gatgctctg gctcagatgc gccgtatctc tctttctccc tgcctgaagg acagacatga ctttggattc ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccctccctgt cctccatgag atgattccac agatcttcaa tctcttcagg acaaaggact catctgctgc ttgggatgag accctcttag acaaatctca cactgaactc taccagcagc tgaatgacct ggaagcctgt gtgatacagg ggttgggggt gacagagact cccctcatga aggaaggact cattctggct gtgaggaaat acttccaaag aatcactctc tatctgaaag agaagaaata cagcctctgt gcttgggagg ttctcagagg aaaaatcctg agatcttttt ctttgcacac aaacttgcac gaaagtctaa gaagtaagga atactgtagg ggcgggtgag gctcccccgg tgggtgttct ggggggggct ccaacatggc agtttatctt tccagagtga agactgggaa tggaaagaaat taccagaggga cgtgttccaa aacaaaaaat ggcctcactt atcaaaaaat gacttccact cctccccaca gacttagatt cccctctgtt acacacccct cagagggact ggaggagaa tacttcaggga atccagacaa cgtatccgag gggcccttgt gctatactac tcatccagaa aagagatatg actactggga cattctttag tgttaaggag aa </p>	<p> 60 120 180 240 300 360 420 480 540 600 660 720 780 822 </p>
50	<p> <210> 32 <211> 1359 <212> DNA <213> human </p>	

<11> 1
 <11> 1
 <11> 118
 <11> human

5

<41> 12

	atgggttttt	atctttttaa	gtttaaat	gggaattgaa	agaattatag	agggagagatg	40
	tccaaaataa	aaaatgttat	gacgtgtcaa	aaatggagtt	ctacttcttc	ccacagacct	100
10	agattcttca	ctgtttacaa	cccttcagag	ggactggagg	agaaactactc	caggaatcca	120
	gacaaagatc	ggcagggggc	ctgggtgtat	actactgac	cagaaaagag	atatgactac	140
	tggacattc	ttaggttga	agaggaattc	atgcaattga	gtggagaaaa	ctatgacggc	160
	aaaaatttca	agaaatgttc	tggacttgaa	tccaggggt	gggaattctc	gggcccacac	180
	gtttatggat	gaatttcttc	gaaattctca	aacaaagaaa	tgaagaaata	taactgtctt	200
15	aaacccgata	ggaggttggg	gcttgggttt	tccacacacc	aaccaacaa	ggcttgggaa	220
	tttttttaca	tccccgggtt	gaaaaaacct	ccacatggtt	ctgggtctga	ctaacagtgt	240
	ctgaatggaa	caggtttaaa	ctatcggggg	aatgtgggtg	ctacgtgttc	ggggcacacc	260
	tttttagaat	ggagtgtaca	gaccccttca	acacataaca	ggaacacaga	aaatttctcc	280
	tgcataaaat	tggatgaaaa	ccacttccgc	aatcttgagc	gaaaaaacgc	cccttgggtg	300
20	catatcaaaa	acaaacaaat	gcccggggag	tactgttaca	tacgtctctg	taactctctc	320
	ctagtattca	cggaaacatc	ggcttactga	gacgtgggtg	gaggtctccc	gggtggttgt	340
	ttttccggcg	gcttcaaat	ggcttgggtg	ctggttccaa	ctcatagctt	ggtagagctt	360
	ggcaatcaga	tgtgtgtgtg	tcaaatgggc	cttatctctc	ttttctctca	cttgaaggac	380
	aaacatgact	tccattcttc	ccaggagagc	tcttgcaacc	agttccaaaa	ggctgaaacc	400
25	acccctgttc	tccatgggat	gaccttgcag	atcttcaatc	tcttcagcac	aaaggatcca	420
	tttctgtgtc	gggacagaga	ctctctagac	aaattcttga	ctgaactctc	ccacagactg	440
	aatuaacttg	aaaccttatc	gatacagggt	gtgggggtga	cagagacttt	cttcatgaag	460
	gaaaacttca	tcttgggtgt	gaggaataac	tccaaaagaa	tcactctctc	tctcaaaagc	480
	aaacaaatca	gccccttggc	ctggggaggt	gctagagcag	aaatcatgag	atctttttct	500
30	ttgtcaacaa	acttgcacga	aagtttaaca	ataaagaa			520

<11> 34
 <11> 312
 <11> DNA
 <11> human

35

<41> 34

	atggcagttt	atcttttcaa	gtttaagact	gggaattgaa	agaattatag	agggagagatg	60
	tccaaaataa	aaaatgggat	gacgtgtcaa	aaatggagtt	ctacttcttc	ccacagacct	100
40	agattcttca	ctgtttacaa	cccttcagag	ggactggagg	agaaactactc	caggaatcca	120
	gacaaagatc	ggcagggggc	ctgggtgtat	actactgac	cagaaaagag	atatgactac	140
	tggacattc	ttaggttga	agaggaattc	atgcaattga	gtggaggggc	ctggagggctc	160
	ggttcttggg	gggcttccaa	catggttggc	gattctgccc	aaactctatg	cttgggttagc	180
	gttctccacc	tgatgtgtgt	ggctcagatg	ggcgttatct	ctctttcttc	ctacttgaac	200
45	gacagacatg	acttgggat	tccatgggat	gaggttggga	aacagttcca	aaagggtgaa	220
	atcttccctg	tcttttatga	gatttatgat	gaaattctca	acatttttca	gacaaaagat	240
	ctcttctgct	cttgggtatga	ggacttgggt	gacaaatttc	gaaacaaat	gtacagggag	260
	cttaaaatcc	tggagggggt	tgtgagggag	gaggaagggg	gtgggtgaaa	tccgttgatc	280
	aatgttgact	ccatctctgc	tgtgaacaaa	ttcttctgtc	gtatctcttc	ctatctctct	300
50	gaggaagaaa	acagctctgt	tcttctctag	cttggtcttg	ctaaatctat	gggttctctg	320
	tcttctctca	ccaaactgga	agaactcttc	gttcttcttg	aa		340

<11> 35
 <11> 311

<10> DNA
<11> human

<400> 35
5 atggcagatt atcttcacga gctgaagatt ggaacggaa agaattacag agggacgag
tcccaaaaca aaaatggcat cactctgcaa aaatggagtt caacttctcc ccaagagact
agattttcaa ctgctacaca cccctcagag ggactggaag agaatctac caggaatcca
gacaacgac cgcaggggcc ctggtgctat actactgac cagaaaagag atatgactac
tgcgacattc tggagtctga agaggaatcc gtagagggtg gtagagggtc cccgggtggt
10 ggtctggtgg ggggtcccaa cagtgcttgt gatctgcgcg aaactcctag cctgggtgag
cctcgcacac tgatgctgct ggtcagatg cgcgttatct ctctttctct ctgcttgag
gacagacatg acttgggatt cccctcaggag ggttttccca accagttcca aaaggctgaa
accatccctg tccctcctga gatgattcag cagatcttca atctcttcag cacaaggac
tcattctgtg cttyggatga gacctctca gacaaattct acactgaact ctaccagcag
15 ctgaacttcc tgggaacctg tggatctcag ggggtggggg tgacagagac tcccttgatg
aaggaggact ccatctgtgc tggaggaag tacttccaaa gaatcactct ctatctgaaa
gagaagaaat acagccctta tggatggag gttgtcagag cagaaatctt gaggatcttt
tctttgcaa caactcga agaaagttt agaagtaagg aa 322

20 <10> 38
<11> 1759
<12> DNA
<13> human

<400> 35
25 atggcagatt atcttcacga gctgaagatt ggaacggaa agaattacag agggacgag
tcccaaaaca aaaatggcat cactctgcaa aaatggagtt caacttctcc ccaagagact
agattttcaa ctgctacaca cccctcagag ggactggaag agaatctac caggaatcca
gacaacgac cgcaggggcc ctggtgctat actactgac cagaaaagag atatgactac
30 tgcgacattc tggagtctga agaggaatct atgacttga gtagagaaaa ctatgacggt
aaaaatttcc agaccatgct tggactggaa tgcagacctt gggacttcca gaggccacac
gctcatggat aatttcttc caaatttcca aacaagaaac tgaagaagaa ttactgttgt
aaccctgata gggagctggc gcttgggtgt tccaccacag accccaacaa ggtgtggcaa
ctttgacaca tccctcgtcg cacaacacct ccaactctct ctggctccac ctaccagctt
35 ctgaaggga ctggtgaaaa ctatggggg aatttgggtg ctacctgtcc cgggcacac
tgtcagcaat gtagtgaca gacctctc acacataaca ggaacacaga aaacttccc
tgcasaaatt tggatgaaaa ctactgcgcg aatcctgag gaaaaagggt ccttgggtgc
cataraacca acagccaagt gcygtgggag tactgtaaga taccgtctct tgactctctc
ccagatctca cggaaacatt ggttactta gaggcgggtg gaggctcccc ggggtggtgt
40 tctggtgggt gctcacaacat ggttctgta ctgcgcgaaa ctcatatctt gggtagccgt
cgcacctga tgtgtctggc ttagatggc cgtatctctc tttctctctg ctggaaggac
agacagact ttggatttct ccaaggaggat ttgggcaac agttccaaaa gctgaaacac
atccctgtcc tccatgggat gatccagcag atcttcaac ttgttaccac caaadattct
tctgtgtgtt gggatgagga cctcctggac aaattctgaa cagaactgta ccaagagctc
45 aacaaacctg aagccctgtg gtagcaggag gagggtgtgt gtagaactct gctgacaaac
gtggacttca tccgtgctat gaagaaatcc ttctgtgta ccaatctata tctgactgag
aagaaataca gcccgtctct ttggagggtt gttcgtgata aaactatgg ttccctctct
ttcttaca acctgcaag aggtctctct ctaaggga 1359

50 <10> 37
<11> 1719
<12> DNA
<13> human

[illegible]

4220 32

622 2157

224 225

215 24530

		<115> human	
	<430> 38		
		ggatccacgga tgagcgccgct gcccgctcta cctctgcttc aaatctctgtt ccgcccgcgac	60
		atgctctgtat accctctaga ctgcacagact gggaaatggaa agaattacag agggatcatg	120
40		ccccaaaaca aaaaatggat cccctgtcaa aaatggattt ccactctctt ccaacacact	180
		agattctctc atgtatagaa cctctcagag ggaatggaga acaattatcg caggaatcca	240
		ctcaacgctc cccagggccc ctggttgctt ctacttctt cagaaaagag atctgaactac	300
		ccccacattc ttgagtgtga agaggaatgt atgactctca ctggagaaaa ctatgacggc	360
		ataattctcc acaaccatct tggactctca tggcagagct gggactctca ggcgcacac	420
45		gtccatggat acattctctt caaatctctc atcagaagcc taaagaagaa ctactgtctt	480
		aaacccacaa gggagctggg ccttggctt ctctccatgt aacccaacca gctctggcaa	540
		ctctgtgaca ccccccggct cacaattctt ccaattctct tggctctctt cccatcagtt	600
		ctgaagggtt atctgtgaaa ctactctctt aatttggtgt tctctctctt cctgtcaaat	660
		ttctctgact ctgctggaaa gacccctcaa tcttatataa ggaacacaca aaattctctt	720
50		tgaaaaatc tggctgaaaa ctactctctt aactctctt caaaaaggtt tctatctctt	780
		ctctccccc acagcccaat cctgtgtctc tctgttctga tctgtctctt tctgtctctt	840
		ctgttatcca ctgaacacaa gctctctctt gctctctctt agcttatctt tctgtctctt	900
		gactgtctac atggcgatg acctctctt cctggctctt ctctctctt cccacacaaa	960
		acgaattctt atctctctct acctctctt cctctctctt cctctctctt cctctctctt	1020

gagagaat; gtagatga	aagaaatac	tgggttac	caggatctta	caaatcccc	1168
tttgcctta ccaagacac	cccggttcg	tggtact	ggaatctaa	caaacctca	1149
ggaacaaa	catgaaggt	tggtacc			1157

5

<210>	39
<211>	479
<212>	DNA
<213>	human

	4000	39	
10	ggatccacca	tgagccggct	gcccgtccctg ctctctctcc aactccctggc cggcccccgc 60
	atgtctgtgt	atctctcaga	gtgcaagact gggcaatgaa agaattacag agggacgatg 120
	tccaaaacaa	aaaatgggat	cacctgtcaa aaatggactt ccactctctc ccacagacct 180
	agattctcac	ctctctacaa	cccctcagag ggactggagg agaactatcg cagggaatcca 240
	accaacnato	cgcagggggc	ctgggtgatc actactgato cagaaaagag atatgactac 300
15	ctggacatcc	ctgagctgtg	agacaaatgt atgcattgca gtggagaaaa ctatgacggc 360
	aaattttcca	agaccatgtc	tgactctgaa tggcaggctt gggactctca gggcccacac 420
	gctcatggat	acatctcttc	caaattttca aacaaqaanc tgaagaagaa ctactgtctg 480
	aaccctcgata	gggagctggc	gccttgggtt ttacccacgc accccaacaa ggcgtgggaa 540
	cttctatgaa	tcctccctct	cacacacact ccaccatctt cnggtccccc ctaccagtgt 600
20	ctgaagggaa	tgggtgaaaa	ctatcgccgg aatctggcgc ttaccgtgtc cggggacacc 660
	tgtcacacac	tgagtgacaa	gaacccctac acacataaca ggacacciga aaattttccc 720
	tccaaaaaat	tgatgaaaa	ctactgccgc aatcttgagg gaaaaagggc cccatggttc 780
	catacaacca	acagcccaagt	gggtggggag tactgtgaag taccgtctctg tgactctctc 840
25	ccagtatcca	cggacacagt	ggcttgaaaa cttggatcc 879

30

<210> 40
<211> 915
<212> DNA
<213> human.

	<400> 40	
	ggatccacca tgagcgcgcct gcccttcctg ctcttgctcc aactcctggt cgcgcgcgc	60
	atgtctaaag aggaatgcat gaattgcagt ggaaaaaact atgagggcaa aatttcaag	120
35	accatgtctc gactggaatg ccaggccttg gactctcaga gccccacacg tcatggatcc	180
	attcttccc aatttcaaaa caagaacctg aagaagaatt acttgcttaa ccccgatag	240
	gagctgcggc ctgtgtgtt caccacggac ccccaacaag cctgggaact ttgtgcac	300
	ccccgttga aaacacctcc accatcttct ggtcccacat accagtgct gaagggaaca	360
	ggtaaaaaat atcgggggaa tctggcgtt accgttccc ggacacacct tcagcaactg	420
40	agtccacaga cccctcacac acataacagg acaccacaaa acttcccctg caaaaatttg	480
	gttaaaaaat attgcgcgaa tcttgacgga aaaaggcccc catgttgcca tacaaccaac	540
	agccaagttg ggtgcgagta ctgaagata cggctccttg actctctccc agtatccag	600
	gaacagtctg ccccacagc acaccttgag cttaaccttg tggtaaggga ctgctacat	660
	ggtgatgac acagctacag aggcacatcc tccaccacca ccacaggaaa gaagtctcag	720
45	tcttggtctt ctatgacacc ataccgacac cagaagaccc cagaaaaact cccaaatgct	780
	ggcctgacaa tgaactactg caggaaatca gctccctata aagccccctg ggtttctcc	840
	acagatccca ggttcacgtg ggagtacttg aacctgaaa aatgtctatg aacagaagcg	900
	ccaaagcttg gctcc	915

50 <110> 41
 <111> 607
 <112> 50A
 <113> human

10

[illegible]

— — — — —

1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 26

1000 1000

422, 117, 23

450 42

[illegible]

(2002) 42

432 2406

5222 JIA ET AL.

229 04745

450 45

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	5
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	---

		gaatcttctga catccctctga tggatcaaac ccttctctctc ttctgtctcc accatccagt	841
		ttcttgaaggg aagagggtgaa aactatctgg ggaatctggg ttctaatcttg tctgggtcaca	842
		actgtctgca ttggagtcca agaccccttc acacacctca cagcacatca caaaccttcc	843
		cctggcaaaa ttggatgaa aactactgac gcaatcttga cggaaaaag gcccctatgt	844
5		gacatacaaa caacagccaa gtgggtggg actactgtaa cctacccctc tctgacccct	845
		ctccagcttc cactcaaac ttgtctcca cagcacccac tgagctaac cctgtgtctc	846
		aggactgcta ccatgtgat ggcacagagc aagcagggac accctctacc accacacag	847
		gaaagaagtg ccatgttgt ccatctatga caccacaccc gccacagagc aacccagaaa	848
		actacccaaa tcttggcttg acaatgaact accgaggaa cccagatgac cctaaaggtc	849
10		cctgggtgtt taacacagac cccagcttca ggtgggacta ctgcaacctg aaaaaatgt	850
		caggaacaga agcgtataaa aagctt	851
		<210> 44	
		<211> 566	
15		<212> DNA	
		<213> human	
		<400> 44	
		cctatgtctga agaagaatgc atgcaactgca gtggagaaaa cctatgacggc aaaattttcca	852
20		agaccatgtc tggactggaa tggcaggcct gggactctca gagccacac gctcatggat	853
		acattctctc caaattttca aacaagaacc tgaagaagaa ttactgttgt aaccccgata	854
		gggagctggc gcttgggtgt ttacaccacg accccaacaa gccctgggaa ctttctgaca	855
		tcccccgtcg cacaacacct ccaccatctt ctgtctccac ctaccagtgt ctgaagggaa	856
		caggtgaaaa ctatcgccgg aatgtggctg ttaccgtgtc cgggcacacc tgtcagcact	857
25		ggagtgcaca gacccctcac acacataaca ggcacccaga aaacttcccc tgcaaaaaatt	858
		tggatgaaaa ctactgcgc aatcctgacg gaaaagggtc cccatgggtc cctacaacca	859
		acagctaaat ggggtgggag tactgttaaga taactctctc cagctatcca	860
		cggaaacaatt ggttaataaa aagctt	861
		<210> 45	
30		<211> 654	
		<212> DNA	
		<213> human	
		<400> 45	
35		cctatgtctga ggaagaatgc atgcaactgca gtggagaaaa ctatgacggc aaaattttcca	862
		agaccatgtc tggactggaa tggcaggcct gggactctca gagccacac gctcatggat	863
		acattctctc caaattttca aacaagaacc tgaagaagaa ttactgttgt aaccccgata	864
		gggagctggc gcttgggtgt ttacaccacg accccaacaa gccctgggaa ctttctgaca	865
40		tcccccgtcg cacaacacct ccaccatctt ctgtctccac ctaccagtgt ctgaagggaa	866
		caggtgaaaa ctatcgccgg aatgtggctg ttaccgtgtc cgggcacacc tgtcagcact	867
		ggagtgcaca gacccctcac acacataaca ggcacccaga aaacttcccc tgcaaaaaatt	868
		tggatgaaaa ctactgcgc aatcctgacg gaaaagggtc cccatgggtc cctacaacca	869
		acagctaaat ggggtgggag tactgttaaga taactctctc cagctatcca	870
45		cggaaacaatt ggttaataaa aagctt	871
		cctatgtctga ggaagaatgc atgcaactgca gtggagaaaa ctatgacggc aaaattttcca	872
		agaccatgtc tggactggaa tggcaggcct gggactctca gagccacac gctcatggat	873
		acattctctc caaattttca aacaagaacc tgaagaagaa ttactgttgt aaccccgata	874
		gggagctggc gcttgggtgt ttacaccacg accccaacaa gccctgggaa ctttctgaca	875
		tcccccgtcg cacaacacct ccaccatctt ctgtctccac ctaccagtgt ctgaagggaa	876
		caggtgaaaa ctatcgccgg aatgtggctg ttaccgtgtc cgggcacacc tgtcagcact	877
		ggagtgcaca gacccctcac acacataaca ggcacccaga aaacttcccc tgcaaaaaatt	878
		tggatgaaaa ctactgcgc aatcctgacg gaaaagggtc cccatgggtc cctacaacca	879
		acagctaaat ggggtgggag tactgttaaga taactctctc cagctatcca	880
		cggaaacaatt ggttaataaa aagctt	881
50		cctatgtctga ggaagaatgc atgcaactgca gtggagaaaa ctatgacggc aaaattttcca	882
		agaccatgtc tggactggaa tggcaggcct gggactctca gagccacac gctcatggat	883
		acattctctc caaattttca aacaagaacc tgaagaagaa ttactgttgt aaccccgata	884
		gggagctggc gcttgggtgt ttacaccacg accccaacaa gccctgggaa ctttctgaca	885
		tcccccgtcg cacaacacct ccaccatctt ctgtctccac ctaccagtgt ctgaagggaa	886
		caggtgaaaa ctatcgccgg aatgtggctg ttaccgtgtc cgggcacacc tgtcagcact	887
		ggagtgcaca gacccctcac acacataaca ggcacccaga aaacttcccc tgcaaaaaatt	888
		tggatgaaaa ctactgcgc aatcctgacg gaaaagggtc cccatgggtc cctacaacca	889
		acagctaaat ggggtgggag tactgttaaga taactctctc cagctatcca	890
		cggaaacaatt ggttaataaa aagctt	891
		<210> 46	
		<211> 618	
		<212> DNA	

10

15

20

25

30

35

40

45

50

5
 10
 15
 20
 25
 30
 35

40
 45
 50

55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320
 325
 330
 335
 340
 345
 350
 355
 360
 365
 370
 375
 380
 385
 390
 395
 400
 405
 410
 415
 420
 425
 430
 435
 440
 445
 450
 455
 460
 465
 470
 475
 480
 485
 490
 495
 500
 505
 510
 515
 520
 525
 530
 535
 540
 545
 550
 555
 560
 565
 570
 575
 580
 585
 590
 595
 600
 605
 610
 615
 620
 625
 630
 635
 640
 645
 650
 655
 660
 665
 670
 675
 680
 685
 690
 695
 700
 705
 710
 715
 720
 725
 730
 735
 740
 745
 750
 755
 760
 765
 770
 775
 780
 785
 790
 795
 800
 805
 810
 815
 820
 825
 830
 835
 840
 845
 850
 855
 860
 865
 870
 875
 880
 885
 890
 895
 900
 905
 910
 915
 920
 925
 930
 935
 940
 945
 950
 955
 960
 965
 970
 975
 980
 985
 990
 995

<210> 52
 <211> 384
 <212> DNA
 <213> human

<411> 52

45
 50

55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320
 325
 330
 335
 340
 345
 350
 355
 360
 365
 370
 375
 380
 385
 390
 395
 400
 405
 410
 415
 420
 425
 430
 435
 440
 445
 450
 455
 460
 465
 470
 475
 480
 485
 490
 495
 500
 505
 510
 515
 520
 525
 530
 535
 540
 545
 550
 555
 560
 565
 570
 575
 580
 585
 590
 595
 600
 605
 610
 615
 620
 625
 630
 635
 640
 645
 650
 655
 660
 665
 670
 675
 680
 685
 690
 695
 700
 705
 710
 715
 720
 725
 730
 735
 740
 745
 750
 755
 760
 765
 770
 775
 780
 785
 790
 795
 800
 805
 810
 815
 820
 825
 830
 835
 840
 845
 850
 855
 860
 865
 870
 875
 880
 885
 890
 895
 900
 905
 910
 915
 920
 925
 930
 935
 940
 945
 950
 955
 960
 965
 970
 975
 980
 985
 990
 995

<211> 31
 <212> 165
 <213> PPT
 <214> human

<400> 53
 Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
 1 5 10 15
 Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
 20 25 30
 Arg His Asp Phe Gly Phe Pro Gln Glu Ala Phe Gly Asn Gln Phe Gln
 35 40 45
 Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
 50 55 60
 Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
 65 70 75 80
 Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
 85 90 95
 Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
 100 105 110
 Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
 115 120 125
 Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
 130 135 140
 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
 145 150 155 160
 Leu Arg Ser Lys Glu
 165

 25
 <210> 54
 <211> 165
 <212> PRT
 <213> human

 30
 <400> 54
 Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
 1 5 10 15
 Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
 20 25 30
 Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
 35 40 45
 Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
 50 55 60
 Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
 65 70 75 80
 Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
 85 90 95
 Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
 100 105 110
 Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
 115 120 125
 Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
 130 135 140
 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
 145 150 155 160
 Leu Arg Ser Lys Glu
 165

(115) 173
 (115) 181
 (115) human
 5
 (115) 58
 Met Ala Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr
 1 5 11 15
 Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu
 10 20 25 30
 Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln
 35 40 45
 Phe Gln Lys Ala Gln Thr Ile Pro Val Leu His Gln Met Ile Gln Gln
 50 55 60
 15 Ile Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu
 65 70 75 80
 Asp Leu Leu Asp Lys Phe Cys Thr Gln Leu Tyr Gln Gln Leu Asn Asp
 85 90 95
 Leu Gln Ala Cys Val Met Gln Gln Gln Arg Val Gly Gln Thr Pro Leu
 100 105 110
 20 Met Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile
 115 120 125
 Thr Leu Tyr Leu Thr Gln Lys Lys Tyr Ser Pro Cys Ala Trp Gln Val
 130 135 140
 25 Val Arg Ala Gln Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln
 145 150 155 160
 Gln Arg Leu Arg Arg Lys Gln Tyr Val Gln Gly Gly Gly Gly Ser Pro
 165 170 175
 Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Val Tyr Leu Ser Gln
 180 185 190
 30 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr
 195 200 205
 Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg
 210 215 220
 35 Pro Arg Phe Ser Pro Ala Thr His Pro Ser Gln Gly Leu Gln Gln Asn
 225 230 235 240
 Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr
 245 250 255
 Thr Asp Pro Gln Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Gln Cys Gln
 260 265 270
 40 Gln Gln
 (115) 56
 45 (115) 453
 (115) PRT
 (115) human
 (115) 56
 50 Met Ala Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr
 1 5 11 15
 Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu
 20 25 30 35
 Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

35 40 45
 106 Gln Lys Ala Gln Thr Ile Pro Val Leu His Gln Met Ile Gln Gln
 50 55 60
 116 Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Gln
 65 70 75 80
 5 Asp Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp
 85 90 95
 126 Glu Ala Cys Val Met Gln Gln Glu Arg Val Gly Glu Thr Pro Leu
 100 105 110
 10 Met Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile
 115 120 125
 136 Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val
 130 135 140
 146 Val Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln
 15 145 150 155 160
 156 Glu Arg Leu Arg Arg Lys Glu Tyr Val Glu Gly Gly Gly Ser Pro
 165 170 175
 186 Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Val Tyr Leu Ser Glu
 180 185 190
 20 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr
 195 200 205
 216 Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg
 210 215 220
 226 Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn
 230 235 240
 25 Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr
 245 250 255
 266 Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu
 260 265 270
 30 Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser
 275 280 285
 296 Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro
 290 295 300
 316 His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys
 305 310 315 320
 35 Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp Cys Phe
 325 330 335
 346 Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys
 340 345 350
 40 Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly
 355 360 365
 376 Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val Ser Gly His
 370 375 380
 396 Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His Asn Arg Thr
 385 390 395 400
 45 Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn
 405 410 415
 426 Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn Ser Gln Val
 420 425 430
 50 Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser Pro Val Ser
 435 440 445
 456 Thr Glu Gln Leu Ala
 450

Figure 1 consists of nine line graphs arranged in a 3x3 grid. The rows represent three countries: Canada (top), France (middle), and the United States (bottom). The columns represent three different years: 1970 (left), 1980 (middle), and 1990 (right). Each graph plots the 'Number of children' on the vertical y-axis (ranging from 0 to 10) against the 'Number of children per adult' on the horizontal x-axis (ranging from 0 to 1.0). The lines in each graph show a general downward trend, indicating that as the number of children per adult increases, the total number of children decreases. The lines are labeled with the country and year, such as 'Canada 1970', 'France 1980', and 'United States 1990'.

5

1000

[illegible]

<010>	18
<011>	483
<012>	997
<013>	Flamar

• 400 •

50

Met Ala Cys Asp Leu Phe Gln Thr His Ser Leu Gly Ser Arg Asn Val
1 2 3 4 5 6 7 8 9 10
Leu Met Leu Leu Ala Gln Met Asn Arg Thr Ser Ile Phe Ser Cys Leu
11 12 13 14 15 16 17 18 19 20
Cys Arg Arg His Asp Phe Gly Thr Glu Gln Glu Ile Gly Asp Glu
21 22 23 24 25 26 27 28 29 30

40 4 45
 Phe Gln Lys Ala Gln Thr Ile Pro Val Leu His Gln Met Ile Gln Gln
 50 55 60
 5 Ile Phe Asn Leu Phe Leu Thr Lys Asp Ser Ser Ala Ala Trp Asp Gln
 65 70 75 80
 Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp
 85 90 95
 Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Gln Thr Pro Leu
 100 105 110
 10 Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile
 115 120 125
 Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val
 130 135 140
 Val Arg Ala Gln Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln
 145 150 155 160
 15 Glu Ser Leu Arg Ser Lys Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro
 165 170 175
 Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Val Tyr Leu Ser Glu
 180 185 190
 20 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr
 195 200 205
 Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg
 210 215 220
 Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn
 225 230 235 240
 25 Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr
 245 250 255
 Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu
 260 265 270
 30 Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser
 275 280 285
 Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro
 290 295 300
 His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys
 305 310 315 320
 35 Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp Cys Phe
 325 330 335
 Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys
 340 345 350
 40 Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly
 355 360 365
 Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val Ser Gly His
 370 375 380
 Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His Asn Arg Thr
 385 390 395 400
 45 Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn
 405 410 415
 Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn Ser Gln Val
 420 425 430
 50 Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser Pro Val Ser
 435 440 445
 Thr Glu Gln Leu Ala
 450

Ala Cys Val Ile Gln Gly Val Gly Val Thr Gln Thr Pro Leu Met Lys
 385 390 395 400
 Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
 405 410 415
 5 Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Gln Val Val Arg
 420 425 430
 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
 435 440 445
 Leu Arg Ser Lys Glu
 450
 10
 <210> 60
 <211> 274
 <212> PRT
 15 <213> human
 <400> 60
 Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15
 20 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 50 55 60
 25 Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu Tyr Val Glu Gly Gly Gly Gly
 85 90 95
 30 Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Cys Asp Leu
 100 105 110
 Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met Leu Leu Ala
 115 120 125
 Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp Arg His Asp
 130 135 140
 35 Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu
 145 150 155 160
 Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe Asn Leu Phe
 165 170 175
 40 Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp Leu Leu Asp Lys
 180 185 190
 Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val
 195 200 205
 Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met Asn Val Asp Ser
 210 215 220
 45 Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr Leu Tyr Leu Thr
 225 230 235 240
 Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile
 245 250 255
 50 Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu Arg Leu Arg Arg
 260 265 270
 Lys Glu

<110>
 <111>
 <112> PPT
 <113> human

5

<410>
 Met Ala Val Tyr Leu Ser Gln Lys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 4 1 18
 Asn Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 21 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Gln Gly Leu Gln Gln Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 51 55 60
 Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Gln Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Gln Cys Gln Gln Gln Tyr Val Gln Gly Gly Gly Gly
 85 90 95
 Ser pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Cys Asp Leu
 101 105 110
 Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met Leu Leu Ala
 115 120 125
 Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp Arg His Asp
 130 135 140
 Phe Gly Phe Pro Gln Gln Gln Phe Gly Asn Gln Phe Gln Lys Ala Gln
 145 150 155 160
 Thr Ile Pro Val Leu His Gln Met Ile Gln Gln Ile Phe Asn Leu Phe
 165 170 175
 Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Gln Thr Leu Leu Asp Lys
 180 185 190
 Phe Tyr Thr Gln Leu Tyr Gln Gln Leu Asn Asp Leu Gln Ala Cys Val
 195 200 205
 Ile Gln Gly Val Gly Val Thr Gln Thr Pro Leu Met Lys Gln Asp Ser
 210 215 220
 Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Lys
 225 230 235 240
 Gln Lys Lys Tyr Ser Pro Cys Ala Trp Gln Val Val Arg Ala Gln Ile
 245 250 255
 Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Gln Ser Leu Arg Ser
 260 265 270
 Lys Gln

<410>
 <411>
 <412> PPT
 <413> human

45

<410>
 Met Ala Val Tyr Leu Ser Gln Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 1 18
 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 21 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro

50

15 40 41
 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asn Asn Pro
 50 55 60
 Gln Gly Pro Trp Cys Tyr Thr Thr Arg Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 5 Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu
 85 90 95
 Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln
 100 105 110
 10 Ala Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys
 115 120 125
 Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg
 130 135 140
 Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu
 145 150 155 160
 15 Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Ser Ser Gly Pro
 165 170 175
 Thr Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val
 180 185 190
 20 Ala Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr
 195 200 205
 Pro His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu
 210 215 220
 Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys
 225 230 235 240
 25 His Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser
 245 250 255
 Cys Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Tyr Val Glu Gly
 260 265 270
 30 Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala
 275 280 285
 Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
 290 295 300
 Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
 305 310 315 320
 35 Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
 325 330 335
 Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
 340 345 350
 40 Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp Leu
 355 360 365
 Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
 370 375 380
 Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met Asn
 385 390 395 400
 45 Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr Leu
 405 410 415
 Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
 420 425 430
 50 Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu Arg
 435 440 445
 Leu Arg Arg Lys Glu
 450

5
 10
 15
 20
 25
 30
 35
 40
 45
 50

Met Glu His Lys Glu Val Val Leu Leu Leu Leu Leu Phe Leu Lys Ser
 1 5 11 15
 Gly Glu Gly Glu Pro Leu Asp Asp Tyr Val Asn Thr Glu Gly Ala Ser
 20 25 30
 Leu Leu Ser Val Thr Lys Lys Glu Leu Gly Ala Gly Ser Ile Glu Glu
 35 40 45
 Cys Ala Ala Lys Cys Glu Glu Asp Glu Glu Phe Thr Cys Arg Ala Phe
 50 55 60
 Glu Tyr His Ser Lys Glu Glu Glu Cys Val Ile Met Ala Glu Asn Arg
 65 70 75 80
 Lys Ser Ser Ile Ile Ile Arg Met Arg Asp Val Val Leu Phe Glu Lys
 85 90 95
 Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
 100 105 110
 Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Glu Lys Trp Ser
 115 120 125
 Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser
 130 135 140
 Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Glu
 145 150 155 160
 Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys
 165 170 175
 Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn
 180 185 190
 Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Glu Ala
 195 200 205
 Trp Asp Ser Glu Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe
 210 215 220
 Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu
 225 230 235 240
 Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu
 245 250 255
 Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr
 260 265 270
 Tyr Glu Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala
 275 280 285
 Val Thr Val Ser Gly His Thr Cys Glu His Trp Ser Ala Glu Thr Pro
 290 295 300
 His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp
 305 310 315 320
 Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala His Trp Cys His
 325 330 335
 Thr Thr Asn Ser Glu Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys
 340 345 350
 Asp Ser Ser Pro Val Ser Thr Glu Glu Leu Ala Pro Thr Ala Pro Pro
 355 360 365
 Glu Leu Thr Pro Val Val Glu Asp Cys Tyr His Gly Asp Gly Glu Ser
 370 375 380

Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Lys Glu Ser
 385 390 395 400
 Trp Ser Ser Met Thr Pro His Arg His Glu Lys Thr Pro Glu Asn Tyr
 405 410 415
 5 Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp
 420 425 430
 Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Thr Glu Tyr
 435 440 445
 Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Ala Ser Val Val Ala Pro
 450 455 460
 10 Pro Pro Val Val Leu Leu Pro Asp Val Glu Thr Pro Ser Glu Glu Asp
 465 470 475 480
 Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr
 485 490 495
 15 Val Thr Gly Thr Pro Cys Glu Asp Trp Ala Ala Glu Glu Pro His Arg
 500 505 510
 His Ser Ile Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys
 515 520 525
 Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr
 530 535 540
 20 Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Glu Cys
 545 550 555 560
 Ala Ala Pro Ser Phe Asp
 565
 25
 <210> 64
 <211> 381
 <212> PRT
 <213> human
 30
 <400> 64
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Glu Leu Leu Val Arg Pro
 1 5 10 15
 Ala Met Ser Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn
 20 25 30
 35 Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Glu Lys
 35 40 45
 Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His
 50 55 60
 40 Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp
 65 70 75 80
 Pro Glu Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp
 85 90 95
 Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly
 100 105 110
 45 Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys
 115 120 125
 Glu Ala Trp Asp Ser Glu Ser Pro His Ala His Gly Tyr Ile Pro Ser
 130 135 140
 50 Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp
 145 150 155 160
 Arg Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp
 165 170 175
 Ala Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly

170 18 19
 His Thr Tyr Glu Tyr Leu Lys Gly Thr Gly Glu Asn Lys Arg Lys Asn
 190 200 210
 Val Ala Val Thr Val Val Gly Ala Thr Lys Glu His Thr Lys Ala Glu
 210 220 230
 Thr Pro His Thr His Asn Arg Thr Pro Glu Asn Pro Pro Lys Lys Asn
 230 240 250
 Leu Asp Glu Asn Tyr Lys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp
 250 260 270
 Cys His Thr Thr Asn Ser Glu Val Arg Trp Glu Tyr Cys Lys Ile Pro
 270 280 290
 Ser Tyr Asp Ser Ser Pro Val Ser Thr Glu Glu Leu Ala Pro Thr Ala
 290 300 310
 Pro Pro Glu Leu Thr Pro Val Val Glu Asp Cys Tyr His Gly Asp Gly
 310 320 330
 Glu Ser Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys
 330 340 350
 Glu Ser Trp Ser Ser Met Thr Pro His Arg His Glu Lys Thr Pro Glu
 350 360 370
 Asn Tyr Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp
 370 380 390
 Ala Asp Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp
 390 400 410
 Glu Tyr Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Ala
 410 420 430
 430 440 450
 460 470 480
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Glu Leu Leu Val Arg Pro
 480 490 500
 Ala Met Ser Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn
 500 510 520
 Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Glu Lys
 520 530 540
 Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His
 540 550 560
 Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asn Asn Asp
 560 570 580
 Pro Glu Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp
 580 590 600
 Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu Lys Met His Cys Ser Gly
 600 610 620
 Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys
 620 630 640
 Glu Ala Trp Asp Ser Glu Ser Pro His Ala His Gly Tyr Ile Pro Ser
 640 650 660
 Lys Pro Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp
 660 670 680
 Arg Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp
 680 690 700

<210> 65

<211> 285

<212> PPT

<213> human

<400> 65

Met Ser Arg Leu Pro Val Leu Leu Leu Leu Glu Leu Leu Val Arg Pro
 1 5 10 15
 Ala Met Ser Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn
 20 25 30
 Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Glu Lys
 35 40 45
 Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His
 50 55 60
 Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asn Asn Asp
 65 70 75 80
 Pro Glu Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp
 85 90 95
 Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu Lys Met His Cys Ser Gly
 100 105 110
 Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys
 115 120 125
 Glu Ala Trp Asp Ser Glu Ser Pro His Ala His Gly Tyr Ile Pro Ser
 130 135 140
 Lys Pro Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp
 145 150 155 160
 Arg Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp
 165 170 175

5
 10
 15
 20
 25
 30
 35
 40
 45
 50

Lys Asn Tyr Asp Tyr Cys Asp Ile Leu Ala Cys Ala Gln Gln Lys Met
 65 90 65
 His Cys Ser Gly Gln Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser
 105 105 110
 Gly Leu Gln Cys Gln Ala Trp Asp Ser Gln Ser Pro His Ala His Gly
 115 120 125
 Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys
 130 135 140
 Arg Asn Pro Asp Arg Gln Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro
 145 150 155 160
 Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro
 165 170 175
 Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly Thr Gly Gln Asn
 180 185 190
 Tyr Arg Gly Asn Val Ala Val Thr Val Ser Gly His Thr Cys Gln His
 195 200 205
 Trp Ser Ala Gln Thr Pro His Thr His Asn Arg Thr Pro Gln Asn Phe
 210 215 220
 Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys
 225 230 235 240
 Arg Ala Pro Trp Cys His Thr Thr Asn Ser Gln Val Arg Trp Gln Tyr
 245 250 255
 Cys Lys Ile Pro Ser Cys Asp Ser Ser Pro Val Ser Thr Glu Gln Leu
 260 265 270
 Ala Pro Thr Ala Pro Pro Glu Leu Thr Pro Val Val Gln Asp Cys Tyr
 275 280 285
 His Gly Asp Gly Gln Ser Tyr Arg Gly Thr Ser Ser Thr Thr Thr
 290 295 300
 Gly Lys Lys Cys Gln Ser Trp Ser Ser Met Thr Pro His Arg His Gln
 305 310 315 320
 Lys Thr Pro Glu Asn Tyr Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys
 325 330 335
 Arg Asn Pro Asp Ala Asp Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro
 340 345 350
 Ser Val Arg Trp Glu Tyr Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu
 355 360 365
 Ala Ser Val Val Ala Pro Pro Pro Val Val Leu Leu
 370 375 380

<210> 69
 <211> 364
 <212> PPT
 <213> human

<400> 69
 Met Ser Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15
 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Gln Gly Leu Gln Gln Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 50 55 60

111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130
 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170
 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190
 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230
 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250
 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290
 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310
 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350
 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370
 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410
 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430
 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450
 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470
 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490
 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510
 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530
 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550
 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570
 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590
 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610
 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630
 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650
 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670
 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690
 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710
 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730
 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750
 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770
 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790
 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810
 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830
 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850
 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870
 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890
 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910
 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930
 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950
 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970
 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990
 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010
 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030
 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050
 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070
 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090
 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110
 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130
 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150
 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170
 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190
 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210
 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230
 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250
 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270
 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290
 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310
 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330
 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350
 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370
 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390
 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410
 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430
 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450
 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470
 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490
 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510
 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530
 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550
 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570
 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590
 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610
 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630
 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650
 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670
 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690
 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710
 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730
 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750
 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770
 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790
 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810
 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830
 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850
 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870
 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890
 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910
 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930
 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950
 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970
 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990
 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050
 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070
 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090
 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110
 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130
 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150
 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170
 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190
 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210
 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230
 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250
 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270
 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290
 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310
 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330
 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350
 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370
 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390
 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410
 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430
 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450
 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470
 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490
 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510
 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530
 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550
 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570
 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590
 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610
 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630
 2631 2632 2633 2634 26

65	70	75	80
Pro Arg Lys Thr Thr Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys			
85	90	95	
Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val			
100	105	110	
Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His			
115	120	125	
Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr			
130	135	140	
Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn			
145	150	155	160
Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser			
165	170	175	
Pro Val Ser Thr Glu Gln Leu Ala			
180			
	<210> 71		
	<311> 230		
	<212> PRT		
	<313> human		
	<400> 71		
Met Ser Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly			
1	5	10	15
Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser			
20	25	30	
Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys			
35	40	45	
Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro			
50	55	60	
Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile			
65	70	75	80
Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys			
85	90	95	
Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val			
100	105	110	
Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His			
115	120	125	
Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr			
130	135	140	
Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn			
145	150	155	160
Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser			
165	170	175	
Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro Glu Leu Thr			
180	185	190	
Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser Tyr Arg Gly			
195	200	205	
Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser Trp Ser Ser			
210	215	220	
Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr Pro Asn Ala			
225	230	235	240
Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Cys Gly Pro			
245	250	255	

$$\frac{1}{2} \left(\frac{1}{2} \right)^2 = \frac{1}{8} \quad \frac{1}{2} \left(\frac{1}{2} \right)^2 = \frac{1}{8} \quad \frac{1}{2} \left(\frac{1}{2} \right)^2 = \frac{1}{8} \quad \frac{1}{2} \left(\frac{1}{2} \right)^2 = \frac{1}{8} \quad \frac{1}{2} \left(\frac{1}{2} \right)^2 = \frac{1}{8}$$

5

10

440

Mat	Sex	Vol	Type	Ln	Sex	Vol	Type	Ln	Sex	Vol	Type	Ln	Sex	Vol	Type
1				1				1				1			
2				2				2				2			
3				3				3				3			
4				4				4				4			
5				5				5				5			
6				6				6				6			
7				7				7				7			
8				8				8				8			
9				9				9				9			
10				10				10				10			
11				11				11				11			
12				12				12				12			
13				13				13				13			
14				14				14				14			
15				15				15				15			
16				16				16				16			
17				17				17				17			
18				18				18				18			
19				19				19				19			
20				20				20				20			
21				21				21				21			
22				22				22				22			
23				23				23				23			
24				24				24				24			
25				25				25				25			
26				26				26				26			
27				27				27				27			
28				28				28				28			
29				29				29				29			
30				30				30				30			
31				31				31				31			
32				32				32				32			
33				33				33				33			
34				34				34				34			
35				35				35				35			
36				36				36				36			
37				37				37				37			
38				38				38				38			
39				39				39				39			
40				40				40				40			
41				41		</									

15

Aug City Tax Mar Apr May Tax Tax Jan City Tax Tax City Tax Tax City Tax Tax City Tax Tax

10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531
----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Arg Ala Gly Leu Glu Glu Asn Tyr Tyr Asn Asn Pro Asp Asn Asp Pro
50 55 60

20

Old	Qty	Pre	Top	Cys	Tyr	Thr	Val	Asp	Phe	Glu	Lys	Arg	Trp	Asp	Tyr
61					71					75					80

Cys Asp Ile Leu Glu Cys Glu Glu Ala Cys Met His Cys Ser Gly Glu
 35 40 45

Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Gln Gln
100 105 110

25

Ala Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys
115 100 125

His Pro Asn Lys Asn Ile Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg
 130 135 140

30

Glu	Leu	Arg	Phe	Trp	Gln	Pro	Thr	Thr	Asp	Phe	Asn	Lys	Arg	Trp	Glu
140				150					155						160

Leu Cys Asp Ile Phe Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro
165 170 175

Thr Tyr Gln Cys Leu Lys Gly Thr Ile Glu Asn Tyr Asx Gly Asn Val
191 185 190

35

Ala Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr
195 200 205

Pro His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Gln Lys Asn Leu
210 215 220

40

Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys
225 230 235 240

His	Tor	Thr	Asn	Ser	Gln	Val	Arg	Tyr	Glu	Tyr	Cys	Lys	Ile	Pro	Gly
216									180					155	

Tyr Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala
150 155

45

```
<C1> 73
<C2> 84
<C3> PRT
<C4> FILTER
```

50

450 73

Met Ser Val Tyr Leu Ser Ala Cys Lys Thr Gly Asn Gly Lys Asn Tyr
1 4 17 18

Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Lys Glu Lys Trp
 10 35 50
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 5 50 55 60
 Gln Gly Phe Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu
 10 85
 <210> 74
 <211> 106
 <212> PRT
 15 <213> human
 <400> 74
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro
 1 5 10 15
 Ala Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn
 20 20 25 30
 Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys
 35 40 45
 Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His
 25 50 55 60
 Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp
 65 70 75 80
 Pro Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp
 85 90 95
 Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu
 30 100 105
 <210> 75
 <211> 470
 35 <212> PRT
 <213> human
 <400> 75
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro
 40 1 5 10 15
 Ala Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn
 20 20 25 30
 Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys
 35 40 45
 Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His
 45 50 55 60
 Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp
 65 70 75 80
 Pro Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp
 85 90 95
 Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly
 100 105 110
 Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys
 115 120 125

	His	Ala	Tyr	Arg	Phe	Gln	Val	Leu	Pro	His	Ala	Glu	Val	Tyr	Gln	Thr	Arg
	141					147								154			
5	Lys	Phe	Tyr	Asn	Leu	Asn	Leu	Lys	Lys	Asn	Tyr	Lys	Ala	Asn	Phe	Asp	
	145					151						157					163
	Arg	Gln	Leu	Arg	Ile	Tyr	Lys	Ile	Thr	Gln	Asp	Val	Asn	Lys	Ala	Ile	
					165						171					178	
	Gln	Leu	Lys	Asp	Ile	Phe	Arg	Cys	Thr	Thr	Phe	Phe	Phe	Ser	Ser	Gly	
				181					188						191		
10	Phe	Thr	Tyr	Gln	Cys	Leu	Lys	Gly	Thr	Gly	Gln	Asn	Lys	Arg	Gly	Asn	
					195				202					208			
	Val	Ala	Val	Thr	Val	Ser	Gly	His	Thr	Cys	Gln	His	Trp	Ser	Ala	Gln	
		211					218					221					
	Thr	Pro	His	Thr	His	Asn	Arg	Thr	Pro	Glu	Asn	Phe	Phe	Cys	Lys	Asn	
	229					231						235				241	
15	Leu	Asp	Gln	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Lys	Arg	Ala	Pro	Trp	
					245					251						258	
	Lys	His	Thr	Thr	Asn	Ser	Gln	Val	Arg	Trp	Gln	Tyr	Cys	Lys	Ile	Pro	
				260					265					270			
20	Ser	Cys	Asp	Ser	Ser	Pro	Val	Ser	Thr	Gln	Gln	Leu	Ala	Tyr	Val	Gln	
			271						280					285			
	Gly	Gly	Gly	Gly	Ser	Phe	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Ser	Asn	Met	
			290				295						300				
	Ala	Cys	Asp	Leu	Pro	Gln	Thr	His	Ser	Leu	Gly	Ser	Arg	Arg	Thr	Leu	
	305					310						315				320	
25	Met	Leu	Leu	Ala	Gln	Met	Arg	Arg	Ile	Ser	Leu	Phe	Ser	Cys	Leu	Lys	
					325						330					335	
	Asp	Arg	His	Asp	Phe	Gly	Ile	Pro	Gln	Glu	Glu	Phe	Gly	Asn	Gln	Phe	
				340					345						350		
30	Gln	Lys	Ala	Glu	Thr	Ile	Pro	Val	Leu	His	Glu	Met	Ile	Gln	Gln	Ile	
				355					360					365			
	Phe	Asn	Leu	Phe	Thr	Thr	Lys	Asp	Ser	Ser	Ala	Ala	Trp	Asp	Glu	Asp	
				370					375					380			
	Leu	Leu	Asp	Lys	Phe	Cys	Thr	Glu	Leu	Tyr	Gln	Gln	Leu	Asn	Asp	Leu	
	385					390						395				400	
35	Gln	Ala	Cys	Val	Met	Gln	Gln	Gln	Arg	Val	Gly	Gln	Thr	Pro	Leu	Met	
				405							410					415	
	Asn	Val	Asp	Ser	Ile	Leu	Ala	Val	Lys	Lys	Tyr	Phe	Arg	Arg	Ile	Thr	
				420						425					430		
40	Leu	Tyr	Leu	Thr	Gln	Lys	Lys	Tyr	Ser	Pro	Cys	Ala	Trp	Glu	Val	Val	
			435						440								

10
 Cys Phe Gln Gln Ala Arg Ala Val Tyr Leu Ala Gly Thr Phe Arg Ala
 30 40
 Phe Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala
 5 50 60
 Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe
 65 70 75 80
 Pro Ser Trp Gln Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro
 85 90 95
 10 Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro
 100 105 110
 Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg
 115 120 125
 Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser
 15 130 135 140
 Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln
 145 150 155 160
 Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn
 165 170 175
 20 Ser Phe Met Thr Ala Ser Lys
 180
 <210> 77
 <211> 810
 25 <212> PRT
 <213> human
 <400> 77
 Met Glu His Lys Glu Val Val Leu Leu Leu Leu Leu Phe Leu Lys Ser
 30 1 5 10 15
 Gly Gln Gly Glu Pro Leu Asp Asp Tyr Val Asn Thr Gln Gly Ala Ser
 20 25 30
 Leu Phe Ser Val Thr Lys Lys Gln Leu Gly Ala Gly Ser Ile Glu Glu
 35 35 40 45
 Cys Ala Ala Lys Cys Glu Glu Asp Glu Glu Phe Thr Cys Arg Ala Phe
 50 55 60
 Gln Tyr His Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Arg
 65 70 75 80
 Lys Ser Ser Ile Ile Ile Arg Met Arg Asp Val Val Leu Phe Glu Lys
 40 85 90 95
 Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
 100 105 110
 Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser
 115 120 125
 45 Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser
 130 135 140
 Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln
 145 150 155 160
 Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys
 50 165 170 175
 Asp Ile Leu Gln Cys Gln Gln Glu Cys Met His Cys Ser Gly Glu Asn
 180 185 190
 Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala
 195 200 205

		Arg	Asp	Thr	Gln	Leu	Pro	His	Ala	Ala	Pro	Gly	Tyr	Ile	Leu	Thr	Leu	Asp
		11							117					117				
		Pro	Asp	Lys	Asn	Leu	Lys	Lys	Asn	Tyr	Gly	Arg	Asn	Pro	Arg	Arg	Gln	
		122				122						121					124	
5		Leu	Arg	Pro	Thr	Gly	Pro	Thr	Thr	Asp	Pro	Asn	Lys	Asn	Thr	Gln	Leu	
						143						139					143	
		Cys	Asp	Ile	Pro	Arg	Lys	Thr	Thr	Pro	Pro	Pro	Ser	Ser	Gly	Pro	Thr	
						146				145					170			
10		Tyr	Gln	Cys	Leu	Lys	Gly	Thr	Gly	Gln	Asn	Tyr	Arg	Gly	Asn	Val	Ala	
		175							181					185				
		Val	Thr	Val	Ser	Gly	His	Thr	Cys	Gln	His	Trp	Ser	Ala	Gln	Thr	Pro	
		190						195						190				
		His	Thr	His	Asn	Arg	Thr	Pro	Gln	Asn	Phe	Pro	Cys	Lys	Asn	Leu	Asp	
		205						210					215				220	
15		Gln	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Lys	Arg	Ala	Pro	Trp	Cys	His	
						225						230				235		
		Thr	Thr	Asn	Ser	Gln	Val	Arg	Trp	Gln	Tyr	Cys	Lys	Ile	Pro	Ser	Cys	
						240						245				250		
20		Asp	Ser	Ser	Pro	Val	Ser	Thr	Gln	Gln	Leu	Ala	Pro	Thr	Ala	Pro	Pro	
		255							260						265			
		Gln	Leu	Thr	Pro	Val	Val	Gln	Asp	Cys	Tyr	His	Gly	Asp	Gly	Gln	Ser	
		270						275						280				
		Tyr	Arg	Gly	Thr	Ser	Ser	Thr	Thr	Thr	Thr	Gly	Lys	Lys	Cys	Gln	Ser	
		285						290					295				300	
25		Trp	Ser	Ser	Met	Thr	Pro	His	Arg	His	Gln	Lys	Thr	Pro	Gln	Asn	Tyr	
						305						310				315		
		Pro	Asn	Ala	Gly	Leu	Thr	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Asp	
						320						325				330		
30		Lys	Gly	Pro	Trp	Cys	Phe	Thr	Thr	Asp	Pro	Ser	Val	Arg	Trp	Gln	Tyr	
						335								340				
		Cys	Asn	Leu	Lys	Lys	Cys	Ser	Gly	Thr	Gln	Ala	Ser	Val	Val	Ala	Pro	
						350								355				
		Pro	Pro	Val	Val	Leu	Leu	Pro	Asp	Val	Gln	Thr	Pro	Ser	Gln	Gln	Asp	
						360								365			370	
35		Cys	Met	Phe	Gly	Asn	Gly	Lys	Gly	Tyr	Arg	Gly	Lys	Arg	Ala	Thr	Thr	
						375								380			385	
		Val	Thr	Gly	Thr	Pro	Cys	Gln	Asp	Trp	Ala	Ala	Gln	Gln	Pro	His	Arg	
						390								395			400	
		His	Ser	Ile	Phe	Thr	Pro	Gln	Thr	Asn	Pro	Arg	Ala	Gly	Leu	Gln	Lys	
40						405								410			415	
		Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Asp	Val	Gly	Gly	Pro	Trp	Cys	Tyr	
						420								425			430	
		Thr	Thr	Asn	Pro	Arg	Lys	Leu	Tyr	Asp	Tyr	Cys	Asp	Val	Pro	Gln	Cys	
						435								440			445	
45		Ala	Ala	Pro	Ser	Phe	Asp	Cys	Gly	Lys	Pro	Gln	Val	Gln	Pro	Lys	Lys	
						450								455			460	
		Cys	Pro	Gly	Arg	Val	Val	Gly	Gly	Cys	Val	Ala	His	Pro	His	Ser	Trp	
						465								470			475	
		Pro	Trp	Gln	Val	Ser	Leu	Arg	Thr	Asn	Phe	Gly	Met	His	Phe	Cys	Gly	
50						480								485			490	
		Gly	Thr	Leu	Ile	Ser	Pro	Gln	Trp	Val	Leu	Thr	Ala	Ala	His	Cys	Leu	
						495								500			505	
		Gln	Lys	Ser	Pro	Arg	Pro	Ser	Ser	Tyr	Lys	Val	Ile	Leu	Gly	Ala	His	
						510								515			520	

5
 10
 15
 20
 25
 30
 35
 40
 45
 50

Gln Glu Val Asn Ser Glu Pro His Val Gln Glu Ile Glu Val Thr Arg
 645 651 655
 Leu Phe Leu Glu Pro Thr Arg Lys Asp Ile Ala Leu Leu Lys Leu Ser
 660 665 670
 Ser Pro Ala Val Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Ser
 675 680 685
 Pro Asn Tyr Val Val Ala Asp Arg Thr Glu Cys Phe Ile Thr Gly Trp
 690 695 700
 Gly Glu Thr Gln Gly Thr Phe Gly Ala Gly Leu Leu Lys Glu Ala Gln
 705 710 715 720
 Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Tyr Glu Phe Leu Asn
 725 730 735
 Gly Arg Val Gln Ser Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly
 740 745 750
 Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu
 755 760 765
 Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys
 770 775 780
 Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val
 785 790 795 800
 Thr Trp Ile Glu Gly Val Met Arg Asn Asn
 805 810

 <210> 78
 <211> 127
 <212> PPT
 <213> human

 <400> 78
 Gly Pro Thr Gly Thr Gly Glu Ser Lys Cys Pro Leu Met Val Lys Val
 1 5 10 15
 Leu Asp Ala Val Arg Gly Ser Pro Ala Ile Asn Val Ala Val His Val
 20 25 30
 Phe Arg Lys Ala Ala Asp Asp Thr Trp Glu Pro Phe Ala Ser Gly Lys
 35 40 45
 Thr Ser Glu Ser Gly Glu Leu His Gly Leu Thr Thr Glu Glu Glu Phe
 50 55 60
 Val Glu Gly Ile Tyr Lys Val Glu Ile Asp Thr Lys Ser Tyr Trp Lys
 65 70 75 80
 Ala Leu Gly Ile Ser Pro Phe His Glu His Ala Glu Val Val Phe Thr
 85 90 95
 Ala Asn Asp Ser Gly Pro Arg Arg Tyr Thr Ile Ala Ala Leu Leu Ser
 100 105 110
 Pro Tyr Ser Tyr Ser Thr Thr Ala Val Val Thr Asn Pro Lys Glu
 115 120 125

 <210> 79
 <211> 13
 <212> PPT
 <213> human

 <400> 79
 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly
 1 5 10 15

5 <211> 41
 <211> 4
 <211> PPT
 <211> human

 10 <411> 81
 Gly Gly Gly Ser
 1

 15 <211> 41
 <211> 4
 <211> PPT
 <211> human

 20 <411> 81
 Gly Gly Gly Ser Gly Gly Gly Ser
 1 5

 25 <211> 81
 <211> 11
 <211> PPT
 <211> human

 30 <411> 82
 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
 1 5 10

 35 <211> 83
 <211> 7
 <211> PPT
 <211> human

 40 <411> 83
 Ser Gly Gly Ser Gly Gly Ser
 1 5

 45 <211> 84
 <211> 6
 <211> PPT
 <211> human

 50 <411> 84
 Gln Phe Gly Asn Met Ala
 1 5

 <211> 85
 <211> 7
 <211> PPT
 <211> human

 <411> 85

ALL THE GLY GLY ASK MET ALA
5

5 <210> 86
 <211> 10
 <212> PRT
 <213> human

<400> 86

10 Glu Phe Gly Gly Asn Gly Gly Asn Met Ala
 :
 5 10

15 <010> 87
 <211> 7
 <010> PRT
 <010> human

<400> 87
Gly Gly Ser Asp Met Ala Gly

20 1 5

25

	<210>	88
	<211>	4
	<212>	PRT
	<213>	human.

<406> 88
 gly Gly Gly Ser
 1

```

<210> 89
<211> 5
<212> PRT
<213> human

```

<410> 89
Gly Gly Gly Gly Ser
: 5

40 <210> 90
 <211> 6
 <212> PRT
 <213> human

45 <400> 90
Gly Gly Gly Gly Gly Ser
 1 5

50

```
<216> 91
<211> 3
<210> PRT
<213> human
<450> 91
```

Ala Gly Ser
 1
 <21> 91
 5 <211> 7
 <212> PPT
 <213> human
 <400> 92
 10 Gly Gly Gly Gly Gly Gly Ser
 1 5
 <210> 93
 <211> 34
 15 <212> PPT
 <213> human
 <400> 94
 20 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly
 1 5 10 15
 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser
 20 25 30
 Gly Gly Gly Ser
 35
 25 <210> 94
 <211> 24
 <212> PPT
 <213> human
 30 <400> 95
 Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro
 1 5 10 15
 Ser Lys Glu Ser His Lys Ser Pro
 20
 35 <210> 96
 <211> 28
 <212> PPT
 <213> human
 40 <400> 96
 Ile Glu Gly Arg Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn
 1 5 10 15
 45 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro
 20 25
 50 <210> 96
 <211> 29
 <212> DNA
 <213> human
 <400> 96
 cagggcattgg caggtatatt cagcatttc

13

5	<210> 97	
	<211> 36	
	<212> DNA	
	<213> human	
10	<400> 97	
	catgacatgg agtttatct tccagagctt	36
	<210> 98	
	<211> 34	
15	<212> DNA	
	<213> human	
	<400> 98	
	gatcaagttt ttattaagcc aattgttcag tggc	34
20	<210> 99	
	<211> 34	
	<212> DNA	
	<213> human	
25	<400> 99	
	gatcaagttt ttattacgtt tctgttcctg agca	34
30	<210> 100	
	<211> 34	
	<212> DNA	
	<213> human	
35	<400> 100	
	gatcaagttt ttattaaagc aggacaacag gagg	34
40	<210> 101	
	<211> 48	
	<212> DNA	
	<213> human	
45	<400> 101	
	gatcacatgt chgargarga rtgyatgcay tgcagtggag aaaactat	48
50	<210> 102	
	<211> 48	
	<212> DNA	
	<213> human	
50	<400> 102	
	gatcacatgt cngtbtayct atncartgy aagactggca atgdaaag	48
50	<210> 103	
	<211> 48	
	<212> DNA	
	<213> human	

<210> 103
 gatggatctg tgccttctga tggcctcttc tgcctctctc cctggcct
 41

5
 <210> 104
 <211> 34
 <212> DNA
 <213> human

10
 <400> 104
 gatggatctg tgccttctga tggcctcttc tgcctctctc cctggcct 34

15
 <210> 105
 <211> 31
 <212> DNA
 <213> human

<400> 105
 gatggatctg tgccttctga tggcctcttc tgcctctctc cctggcct 31

20
 <210> 106
 <211> 25
 <212> DNA
 <213> human

25
 <400> 106
 gatggatctg tgccttctga tggcctcttc tgcctctctc cctggcct 25

30
 <210> 107
 <211> 40
 <212> DNA
 <213> human

<400> 107
 gatggatctg tgccttctga tggcctcttc tgcctctctc cctggcct 40

35
 <210> 108
 <211> 27
 <212> DNA
 <213> human

40
 <400> 108
 gatggatctg tgccttctga tggcctcttc tgcctctctc cctggcct 27

45
 <210> 109
 <211> 33
 <212> DNA
 <213> human

50
 <400> 109
 gatggatctg tgccttctga tggcctcttc tgcctctctc cctggcct 33

<210> 110
 <211> 30
 <212> DNA

<210> human

<400> 110
 catggccatgg cagtttatct tccagaggtgt 10

5

<210> 111
 <211> 34
 <212> DNA
 <213> human

10

<400> 111
 gatcaagatt ttattattcc tcttcacact caag 24

15

<210> 112
 <211> 281
 <212> DNA
 <213> human

20

<400> 112
 ccattggtact ttatttttca gactgttaaga ctgggaatgg aaagaattac agagggacga 60
 tgcctcaaaac aaaaaatggc atcacctgtc aaaaatggag ttccacttct cccacacagac 120
 ctagattctc acctgctaca caccctccag agggactgga ggagaactac tgcaggaatc 180
 cagacaaaca tccgcagggg ccttgggtgt atactactga tccagaaaag agatatgact 240
 actgogacat tcttgagtgt gaagaggaat aataaaaagt t 281

25

<210> 113
 <211> 89
 <212> PRT
 <213> human

30

<400> 113
 Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15
 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 50 55 60
 Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu
 85

35

40

INTERNATIONAL SEARCH REPORT

nt International Application No.

PCT/US 98/20464

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/62 C12N9/68 C07K14/56 C07K14/78 C07K14/52 A61K48/00 A61K38/17 A61K38/19		
According to International Patent Classification (IPC) and both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BUSSOLINO F ET AL: "Molecular mechanisms of blood vessel formation" TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 22, no. 7, July 1997, page 251-256 XP004081592 see table 2	1-28
X	EP 0 141 484 A (BIOGEN NV) 15 May 1985 see the whole document	5,12,13
X	FORSGREN M ET AL: "MOLECULAR CLONING AND CHARACTERIZATION OF A FULL-LENGTH CDNA CLONE FOR HUMAN PLASMINOGEN" FEBS LETTERS, vol. 213, no. 2, March 1987, pages 254-260, XP000052800 see figure 4	5,12,13
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
"X" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "Y" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Z" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
12 January 1999		22/01/1999
Name and mailing address of the ISA European Patent Office, P.B. 5816 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx 31 651 eponi, Fax: (+31-70) 340-3016		Authorized officer: Smalt, R

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 16-24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

The search of claims 21-28, referring to a multi-functional protein, has been restricted to the fusion proteins of claim 1 due to insufficient characterization of the multi-functional protein.

INTERNATIONAL SEARCH REPORT

Information on patent family members

nte International Application No

PCT/US 98/20464

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0141484	A	15-05-1985	JP 60070083 A	20-04-1985
WO 9216221	A	01-10-1992	AU 1674292 A	21-10-1992
			AU 6202396 A	31-10-1996
			CA 2106079 A	16-09-1992
			EP 0575545 A	29-12-1993
			FI 934015 A	14-09-1993
			JP 6506218 T	14-07-1994
			NO 933270 A	01-11-1993
			SG 47099 A	20-03-1998
WO 9635774	A	14-11-1996	US 5837682 A	17-11-1998
			AU 5579596 A	29-11-1996
			CA 2219081 A	14-11-1996
			CZ 9703340 A	15-04-1998
			EP 0824546 A	25-02-1998
			HU 9800784 A	28-07-1998
			NO 974943 A	18-12-1997
			PL 323256 A	16-03-1998
WO 9700691	A	09-01-1997	US 5824299 A	20-10-1998
			CA 2225401 A	09-01-1997
			EP 0841935 A	20-05-1998
WO 9715666	A	01-05-1997	AU 7466696 A	15-05-1997
			CZ 9801177 A	12-08-1998
			EP 0857210 A	12-08-1998
			NO 981803 A	17-06-1998
WO 9730085	A	21-08-1997	US 5837680 A	17-11-1998
			AU 2275397 A	02-09-1997
EP 0297882	A	04-01-1989	AU 615919 B	17-10-1991
			AU 1853388 A	19-01-1989
			DE 3883453 D	30-09-1993
			DE 3883453 T	17-03-1994
			DK 359888 A	02-01-1989
			FI 883146 A	02-01-1989
			JP 1080287 A	27-03-1989
			PT 87869 A,B	30-06-1989
			US 5302390 A	12-04-1994

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/20464

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
SEE FURTHER INFORMATION SHEET PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Patent Application No.

PCT/US 98/20464

C. Continuation, DOCUMENTS CONSIDERED TO BE RELEVANT

Category: Character of document, with indication where appropriate, of the relevant passages

Relevant to claim No.

A WO 92 16221 A (SINERGEN INC)
1 October 1992
see the whole document

A WO 96 35774 A (CHILDRENS MEDICAL CENTER)
14 November 1996
cited in the application
see page 10, line 1 - line 2

A WO 97 00691 A (HARVARD COLLEGE)
9 January 1997
see claims 15,16

A WO 97 15666 A (CHILDRENS MEDICAL CENTER)
1 May 1997
see claims 17,25,31

A WO 97 30085 A (CHILDRENS MEDICAL CENTER)
21 August 1997
see page 11, line 8 - line 16

A EP 0 297 882 A (BEECHAM GROUP PLC)
4 January 1989
see the whole document

P,X BACHELOT, T. ET AL.: "Retrovirus-mediated
gene transfer of an angiostatin-endostatin
fusion protein with enhanced anti-tumor
properties in vivo."
PROCEEDINGS OF THE AMERICAN ASSOCIATION OF
CANCER RESEARCH,
vol. 39, March 1998, pages 271-2,
XP002089298
see the whole document

1,2,6,7,
9,10,13,
21-28